Attached files

file filename
EX-31.1 - Conmed Healthcare Management, Inc.v178146_ex31-1.htm
EX-32.1 - Conmed Healthcare Management, Inc.v178146_ex32-1.htm
EX-23.1 - Conmed Healthcare Management, Inc.v178146_ex23-1.htm
EX-31.2 - Conmed Healthcare Management, Inc.v178146_ex31-2.htm
EX-32.2 - Conmed Healthcare Management, Inc.v178146_ex32-2.htm
EX-21.1 - Conmed Healthcare Management, Inc.v178146_ex21-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-K

 
x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: December 31, 2009
or
 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                    to                   

Commission File Number: 0-27554
Conmed Healthcare Management, Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
42-1297992
(State or other jurisdiction of
 
(IRS Employer
incorporation or organization)
 
Identification No.)

7250 Parkway Dr., Suite 400
   
Hanover, MD
 
21076
(Address of principal executive offices)
 
(Zip code)

410-567-5520
(Registrant's telephone number,
including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Name of each exchange
on which registered
Common Stock, $.0001 par value
 
NYSE Amex LLC
 
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes o   No x

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes o   No x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  o   No  o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405)  is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o  Accelerated filer o   Non-accelerated filer o Smaller reporting company x
(Do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o   No x

The aggregate market value of the voting and non-voting common stock held by non-affiliates, based upon the closing sale price of the common stock on June 30, 2009 was approximately $21,263,200.  Shares of common stock held by each officer and director and by each person who owns 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates.

The number of shares outstanding of the registrant's Common Stock, $.0001 par value, as of March 25, 2010:  12,629,572

DOCUMENTS INCORPORATED BY REFERENCE
The following document is incorporated herein by reference:
Document
 
Parts Into Which Incorporated
Proxy Statement for the Company’s 2010
Annual Meeting of Stockholders
 
Part III

 
 

 

CONMED HEALTHCARE MANAGMENT, INC.

2009 FORM 10-K ANNUAL REPORT

TABLE OF CONTENTS

   
Page
     
PART I.
     
ITEM 1.
Business.
1
     
ITEM 1A.
Risk Factors.
9
     
ITEM 1B.
Unresolved Staff Comments.
16
     
ITEM 2.
Properties.
16
     
ITEM 3.
Legal Proceedings.
16
     
ITEM 4.
Reserved.
16
     
PART II.
     
ITEM 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
17
     
ITEM 6.
Selected Financial Data.
17
     
ITEM 7.
Management's Discussion and Analysis or Financial Condition and Results of Operations.
17
     
ITEM 7A.
Quantitative and Qualitative Disclosures About Market Risk.
25
     
ITEM 8.
Financial Statements and Supplementary Data.
26
     
ITEM 9.
Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.
49
     
ITEM 9A(T).
Controls and Procedures.
49
     
ITEM 9B.
Other Information.
49
     
PART III
     
ITEM 10.
Directors, Executive Officers and Corporate Governance.
50
     
ITEM 11.
Executive Compensation.
50
     
ITEM 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
50
     
ITEM 13.
Certain Relationships and Related Transactions, and Director Independence.
51
     
ITEM 14.
Principal Accountant Fees and Services.
51
     
PART IV
     
ITEM 15.
Exhibits and Financial Statement Schedules.
52
     
 
SIGNATURES
55

 
 

 

PART I.

ITEM 1.         BUSINESS.
 
The Company

Conmed Healthcare Management, Inc. (together with its consolidated subsidiaries, “Conmed”, the “Company”, “we”, “us”, or “our”, unless otherwise specified or the context otherwise requires) provides healthcare services to county and municipal detention centers across the United States. As a result of the Supreme Court decision in Estelle v. Gamble (1976), all individuals held against their will are required to be provided with community standard healthcare. Under this requirement, all counties and municipalities are required to provide healthcare services for their inmates. We are a specialist in the provision of these services.

Corporate History

Prior to January 26, 2007, the Company formerly known as Pace Health Management Systems, Inc. (“Pace”) was classified as a shell company, had no ongoing operations, minimal operating expenses and no employees.

On January 26, 2007, we acquired Conmed, Inc. (“Conmed, Inc.”), a privately-owned provider of correctional healthcare services (the “Acquisition”). Conmed, Inc. was formed as a corporation on June 10, 1987 in the State of Maryland for the purpose of providing healthcare services exclusively to county detention centers located in Maryland. As Conmed, Inc. developed, it accepted more contracts for additional services including mental health, pharmacy and out-of-facility healthcare. In 2000, Conmed, Inc. served more than 50% of the county detention healthcare services market in Maryland. In 2003, Conmed, Inc. elected to seek contracts outside of Maryland and at the time of the Acquisition operated in four states: Kansas, Maryland, Virginia and Washington.  For the fiscal year ended December 31, 2007, Conmed, Inc. had net revenues primarily from medical services provided to correctional institutions of $26,073,040.

As a result of the Acquisition, Conmed, Inc. is a wholly-owned subsidiary of the Company and the business of Conmed, Inc. is now our primary business. On March 13, 2007, the Company changed its name to Conmed Healthcare Management, Inc. In 2008, we purchased all of the assets of Emergency Medicine Documentation Consultants, P.C. (“EMDC”), a provider of medical services in northwest Oregon, and we purchased all of the stock of Correctional Mental Health Services, LLC (“CMHS”), a provider of mental health services in Maryland.  As of December 31, 2009, we were in contract with, and providing medical services in thirty-six counties in seven states including: Arizona, Kansas, Maryland, Oklahoma, Oregon, Virginia and Washington and had net revenues primarily from medical services provided to correctional institutions of $52,784,559.
 
Corporate Information
 
Our principal executive offices are located at 7250 Parkway Drive, Suite 400, Hanover, Maryland 21076. Our telephone number at such address is (410) 567-5520.
 
Services Provided

County and Municipal Correctional Healthcare Services

We provide the following array of healthcare services for inmates in county and municipal facilities under contract with the counties served. The contracts are primarily multiple year, fixed-cost contracts with annual escalations, caps on out-of-facility healthcare and catastrophic expenses that limit our maximum financial exposure, and contain adjustments on a per diem basis for changes in inmate population served.

 
1

 

Correctional healthcare services include a broad array of services that support the care of inmates detained in county detention centers. Correctional healthcare services include, but are not limited, to the following categories:

·    General Healthcare Services
·    Dialysis Services
·    Acute Care Services
·    Durable Medical Equipment
·    Surgical Services
·    Hospital Services
·    Laboratory Services
·    Mental Health Services
·    IV Therapy
·    Pharmacy
·    EKG's
·    Physical and Occupational Therapy
·    Diagnostic Imaging/Radiology
·    Dental Services
·    Electronic Medical Records
·    Electronic Medication Administration Records

We either directly provide these services within the detention facilities or subcontract for the provision of these services within or outside the facility.  We make every effort to safely provide the medical services within the facilities due to security and cost considerations of out-of-facility services.

Contracting

Most of our contracts are awarded through a competitive bidding process in connection with responding to a Request for Proposals (“RFP”).  We have a model for predicting healthcare costs based on 25 years of accumulated experience, external data on healthcare costs, trending, and knowledge of current and future drivers of cost. This predictive model is the basis for the cost proposals we provide in competitive bids. The model addresses and aggregates costs related to staffing, on-site costs, out-of-facility costs, pharmacy, supplies, administrative costs, taxes, and contract fees. We have found that having predictive reliability of costs provides for a higher probability of sustained profits.

Staffing

We provide staffing of healthcare professionals at each of our contracted facilities. The staffing patterns are typically defined within the RFP distributed by the counties and municipalities soliciting proposals for inmate healthcare services. The level of staffing varies depending on the size of the facility, i.e., larger facilities typically require a larger staff. The ratio of staff members to inmates varies depending on the physical structure of the facilities and the specific scope of services required by the RFP. Generally, we engage existing staff at the facility to the greatest extent possible when entering into a new contract. The on-site staffing for any facility may include Registered Nurses, Licensed Practical Nurses, Certified Medication Technicians, Certified Nursing Assistants, nursing assistants, physicians, physician assistants, dentists, psychiatrists, psychologists, social workers, nurse practitioners, medical records' clerks, administrative and support staff.

Pharmacy

We provide medications for inmates within our contracted detention facilities. Medications are currently provided from two national pharmacy contractors, Diamond Pharmacy and Correct Rx, which specialize in the provision of pharmaceutical services to detention centers.  We have accumulated information regarding pharmacy expenses in our contracted facilities, which is useful in the cost proposal portions of our bids.

In-Facility Services

We provide comprehensive healthcare services from the time an inmate enters the facility until the time of such inmate's release from the facility. In some cases, we are responsible for the cost of providing healthcare services to an individual at the time of his or her arrest. The vast majority of healthcare services are provided on site by our clinical staff.  Our healthcare services begin at intake with a screening examination and triage. Such services are continued through the provision of daily sick calls. Typically inmates receive a comprehensive physical examination within 14 days of admission to the facility and a dental examination within 90 days of admission. The initial and subsequent examinations include psychiatric screening evaluations to detect suicide potential and major psychiatric illness requiring special treatment.

 
2

 

The costs for services provided within the facility are generally regionally-based and fairly predictable. The highest costs relate to providing medical and administrative support staff, professional liability insurance, laboratory fees, and on-site radiology plus medical and office supplies.

Out-of-Facility Services
 
Inmates requiring services outside the facility fall into two broad categories: (i) emergencies and (ii) circumstances that require services beyond the capability of those that can be provided in the facility. Out-of-facility services include hospitalizations, emergency room visits and visits for specialty and sub-specialty care plus other ancillary medical services, Most of our out-of-facility services are provided through the use of a local or regional contracted network of professional medical providers using third party administrators (“TPA). In addition, utilization management and utilization review services are employed to assist with case management and assure that care is provided within generally accepted community standards.
 
1.           Case management and utilization reviews - To assure the most cost effective and medically appropriate length of stays, we often utilize the services of a contracted professional utilization management and utilization review (“UM/UR”) organization. When an inmate is hospitalized, the UM/UR organization maintains daily contact with the provider and the Medical Director for the site to assure appropriate care is rendered.

2.           TPA - We contract with TPAs serving most of the areas where the facilities in which we provide healthcare services are located. The TPAs provide a network of physicians, hospitals and ancillary services that are paid based on contracted fee schedules. These fee schedules typically include discounts that average approximately 15% off the submitted charges. The TPA is compensated based on a percent of our savings for the repriced claims.

Mobile Imaging

We provide mobile imaging services, primarily x-ray, which enables the facility to avoid the cost associated with the purchase and housing of expensive equipment and/or the use of correction staff required to accompany inmates during out-of-facility visits.

Dental Services

We provide on-site dental services for many of the facilities we service. Such facilities maintain dental suites with equipment for conducting dental procedures and x-rays depending on the RFP requirements.

Electronic Medical Records

We have launched an initiative to accelerate the adoption of electronic medical records (“EMR”) and electronic medication administrator record (“EMAR”) systems by our client facilities.  Adoption and use of EMR systems in correctional facilities is an important contemporary issue for correctional facility administrators, as use of EMR systems occurs in parallel in the community healthcare system.  It is widely accepted that the use of EMR and EMAR systems in the correctional setting greatly improves productivity and accuracy as well as simplifies the quality measurement and tracking reports necessary for accreditation standards.  The availability of cost effective, user friendly and accreditation compatible EMR systems suitable for use in the correctional medicine arena have lagged behind community oriented systems, but we have identified a commercially available software package and have begun to use it in selected contracted facilities.

EMR systems greatly simplify the tracking of care of patients with chronic conditions, sick calls, chart notes, health problems, release forms, test results, completion of physician orders and appointments with specialist providers.  EMAR systems allow for the tracking of medications ordered, pending shipments and pharmacy deliveries.  When medications are delivered and logged in, they are automatically listed on the medication pass log for the next scheduled medication pass.  Documentation detailing which inmates received medications and when, the type of medication received and from which staff member, as well as which inmates refused medications or were not present not only contributes to the quality of care but also helps mitigate grievances and claims of denial of care.

 
3

 

Additional Services

Value-added services that we provide to our clients include the following:

 
·
Healthcare services consultations - On request from the facility administration, we will provide consultations on healthcare issues such as Tuberculosis, Avian Flu, AIDS, Hepatitis, Methadone treatment, H1N1, reentry programs and many other topics pertinent to correctional healthcare patients. These consultations typically relate to policy issues affecting multiple facilities. In many cases, we have provided expert testimony to state legislative bodies and agencies.

 
·
Audit compliance programs - We provide an audit compliance program as part of our core responsibility to all sites. We have experts in all state and national audit processes on staff. These individuals provide guidance to the sites to assure 100% audit compliance. Additionally, a comprehensive continuous quality improvement program is employed to monitor all healthcare activities to ensure delivery of high quality healthcare services for correctional facilities we serve.

 
·
OSHA compliance programs - Regulation 1910.1030 of the U.S. Department of Labor, Occupational Safety & Health Administration ("OSHA"), provides guidelines and universal precautions that must be observed to prevent contact with blood or other potentially infectious materials. Such regulations are applicable to all occupational exposure to blood or other potentially infectious materials.  We comply with OSHA and provide to our staff members and make available to corrections staff, among other things, appropriate personal protective equipment such as gloves, gowns, laboratory coats, face shields or masks and eye protection, as well as mouthpieces, resuscitation bags, pocket masks, or other ventilation devices. The purpose of such protective equipment is to prevent blood or other potentially infectious materials from passing through to or reaching our employee's or corrections staff’s clothing, undergarments, skin, eyes, mouth, etc.  Other procedures we implement in accordance with OSHA include, but are not limited to, protection from airborne pathogens, ensuring a clean and sanitary worksite and procedures for discarding contaminated waste.

 
·
Risk management - We promote risk management through a process that includes daily monitoring of significant healthcare events, as well as weekly and monthly review of trends and subsequent measured actions. Through attention to detail in the provision and documentation of healthcare, adherence to standards of care and monitoring of events, we are able to substantially reduce the risk of poor outcomes and/or litigation.

 
·
Sick call services for facility staff - We provide limited sick call services to detention center staff for acute problems. This often allows the staff to continue at work rather than taking a sick day for a doctor's visit. This value-added service is appreciated by the facility staff and administration.

 
·
Emergency services for staff and visitors - We believe it is imperative that our medical staff be well trained and equipped to handle emergencies. Thus, we ensure that our medical staff is familiar with the correctional facility and is equipped to deliver prompt emergency care anywhere in the facility. Specific equipment is maintained and restocked when necessary, within each facility in the event of an emergency, including an emergency kit capable of maintaining basic life support.

Sales and Marketing

Our sales and marketing efforts for correctional healthcare services are based on the following:

1.
Market opportunities - We have designated Arizona, Florida, Georgia, Kansas, Kentucky, Iowa, North Carolina, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Virginia and Washington as our primary targets. We are focused on opportunities with the following types of facilities:

a.
Facilities of 500 inmates or more that are currently not served by a correctional healthcare contractor;

b.
Facilities of 500 inmates or more that are served by a local hospital or healthcare provider;

 
4

 

c.
Facilities of 500 inmates or more where a competitor's services are not meeting the facility's expectations; and

d.
Facilities of 500 inmates or more that are served by a competitor that has shifted its focus from the county detention center market to prisons.

2.
Word of mouth – We have a contact network through our existing contracts and through strategic relationships with national pharmacy contractors. This network has provided early indications of counties and municipalities considering outsourcing healthcare services, changing their current contractors or seeking proposals for other reasons.

3.
Online procurement services – We have a contract with an on-line government contracting research service to establish early determinations of county intentions to seek proposals.

4.
Trade meetings – Our staff attends annual regional and national trade meetings. These meetings serve as an opportunity to meet and greet new potential clients. Our trade show booth attracts attention with a variety of marketing tools and techniques. We often sponsor special events and awards at these meetings.

5.
Cold calls – We use, to a limited extent, cold calls, typically only in cases where some collateral indication of a probability of interest exists.

6.
Advertising in trade journals.

7.
Public speaking engagements for special topics on request.

8.
Website promotion of our capabilities and experience.

We currently utilize our CEO, Chief Medical Officer, President of Mental Health Services, and Vice President of Strategic Development, as well as a network of regional consultants to implement our marketing strategy.

Acquisitions

We are also open to selective acquisitions to enhance our growth in strategic areas and have established a pipeline of potential acquisition candidates. In 2008, we purchased all of the assets of EMDC, a provider of medical services in northwest Oregon, and we purchased all of the stock of CMHS, a provider of mental health services in Maryland.  In January 2010, we purchased all of the assets of a small mobile imaging company to expand the base of services that we provide to our customers, which were previously subcontracted, and we do not expect this acquisition to have a material impact on our financial position or results of operations.

Competition

We are aware of four major sources of competition:

1.
National contracting companies that serve both the county and state prison systems. While we are aware of several national companies that provide healthcare services to county detention centers, we do not believe this is their main focus. These companies, including Prison Health Services, Inc., Correctional Medical Services, Inc., Wexford Health Sources, Inc., Naphcare, Inc. and Armor Correctional Health Services, are primarily in the business of providing services to state prisons.

2.
Local or regional companies focused on county detention centers. There are a few companies that provide healthcare services to county detention centers within confined regions, such as California Forensic Medical Group Inc. in California; Correct Care Solutions, LLC in Tennessee; CorrectHealth, LLC in Georgia: Correctional Healthcare Management, Inc. in Colorado; and Primecare Medical, Inc. in Pennsylvania. These companies are privately held and can be characterized as small to medium size businesses when compared to the major national prison healthcare companies. In addition, there are other smaller local groups in markets which we are targeting at this time.

3.
Local hospitals. We have seen several incidences of local hospital systems providing healthcare services to the county detention centers. Such incidences arose out of the absence of other interested providers. The hospital costs for these counties are often extremely high and counties seeking cost savings may seek the services of a professional medical service contractor other than the local hospital.

 
5

 

4.
Local physicians. In some cases, our competitor is a local solo physician or group of physicians. Such contractors typically provide only the on-site sick call services and may have limited expertise in the provision of full service correctional healthcare. Such physicians are often unable to obtain cost effective and appropriate liability insurance that will cover both their primary work, as well as their correctional healthcare services.

Intellectual Property

Conmed has not registered any trademarks, patents, or any other intellectual property.

Government Regulation

The industries in which we operate are subject to extensive federal, state and local regulations and/or orders of judicial authorities, including healthcare, pharmaceutical and safety regulations and judicial orders, decrees and judgments. Some of the regulations and orders are unique to our industries, and the combination of regulations and orders we face is unique. Generally, prospective providers of healthcare and pharmaceutical services to correctional facilities must be able to detail their readiness to, and must comply with, a variety of applicable state and local regulations and state and national standards. Our contracts typically include reporting requirements, supervision and on-site monitoring by representatives of the contracting governmental agencies. In addition, the doctors, nurses, pharmacists and other healthcare professionals who provide healthcare services on our behalf are, in all cases, required to obtain and maintain professional licenses and are subject to state regulation regarding professional standards of conduct. Our services are also subject to operational and financial audits by the governmental agencies with which we have contracts and by the courts of competent jurisdiction. Additionally, services provided to health benefit plans in certain cases, are subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). We may not always successfully comply with these regulations and failure to comply can result in material penalties, non-renewal or termination of contracts with correctional facilities or prohibition from proposing for new business in certain jurisdictions.

Health Insurance Portability and Accountability Act of 1996. The Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) require the use of uniform electronic data transmission standards for healthcare claims and payment transactions submitted or received electronically. These provisions are intended to encourage electronic commerce in the healthcare industry. HIPAA also includes regulations on standards to protect the security and privacy of health-related information. The privacy regulations extensively regulate the use and disclosure of individually identifiable health-related information, whether communicated electronically, on paper or orally.

Corporate Practice of Medicine/Fee Splitting. Many of the states in which we operate have laws that prohibit unlicensed persons or business entities, including corporations, from employing physicians or laws that prohibit certain direct or indirect payments or fee-splitting arrangements between physicians and unlicensed persons or business entities. Possible sanctions for violations of these restrictions include loss of a physician's license, civil and criminal penalties and rescission of business arrangements that may violate these restrictions. These statutes vary from state to state, are often vague, and seldom have been interpreted by the courts or regulatory agencies. We review, on an ongoing basis, the applicable laws in each state in which we operate and review our arrangements with our healthcare providers to ensure that these arrangements comply with all applicable laws. We have no assurance that governmental officials responsible for enforcing these laws will not assert that we, or transactions in which we are involved, are in violation of such laws, or that such laws ultimately will be interpreted by the courts in a manner consistent with our interpretations.

Regulation of Bid Process and Contracting. Contracts with governmental agencies are obtained primarily through a competitive proposal/bidding process, which is governed by applicable state and local statutes and ordinances. Although practices vary, typically a formal RFP is issued by the governmental agency, stating the scope of work to be performed, length of contract, performance bonding requirements, minimum qualifications of bidders, selection criteria and the format to be followed in the bid or proposal. Usually, a committee appointed by the governmental agency reviews proposals and makes an award determination. The committee may award the contract to a particular bidder or decide not to award the contract. The committees consider a number of factors, including the technical quality of the proposal, the offered price and the reputation of the bidder for providing quality care. The award of a contract may be subject to formal or informal protest by unsuccessful bidders through a governmental appeals process. If the committee does not award a contract, the correctional agency may, among various options, continue to provide healthcare services to its inmates with its own personnel or the existing provider.  Certain RFPs and contracts require the bidder to post a bid bond or performance bond. Performance bonding requirements may cover one year or up to the length of the contract.

 
6

 

Our contracts with governmental agencies often require us to comply with numerous additional requirements regarding recordkeeping and accounting, non-discrimination in the hiring of personnel, safety, safeguarding confidential information, management qualifications, professional licensing requirements, emergency healthcare needs of corrections employees and other matters. If a violation of the terms of an applicable contractual or statutory provision occurs, a contractor may be disbarred or suspended from obtaining future contracts for specified periods of time in the applicable location. We have never been disbarred or suspended from seeking procurements in any jurisdiction.

OSHA.  OSHA Standard 29 CFR 1910 requirements include, but are not limited to, protections against exposure to blood borne and airborne pathogens (e.g., tuberculosis), needle stick prevention, fire safety, hazard communications, respiratory protection, and hazardous waste operations. The federal OSHA standards have been adopted by state regulatory agencies to conduct routine environmental inspections.

National Fire Protection Association (“NFPA”). Environmental fire safety is promulgated by the NFPA 101: Life Safety Code derived from the American National Standards Institute (“ANSI”). Enforcement of NFPA regulation is accomplished by annual inspections conducted by the state.

Major Contracts

Substantially all of our operating revenue is derived from contracts with county and municipal governmental entities. Our top three clients generated approximately thirty-eight percent of our total revenues for the year ended December 31, 2009. Summaries of our largest contracts follow below.

Baltimore County Detention Center Contract.  We entered into a Services Agreement with the Board of County Commissioners of Baltimore County, Maryland (“BCDC”), on March 29, 2007, for a period of approximately two years and six months, and BCDC, at its option, may extend the agreement annually for two additional three-year terms upon written notice.  On September 11, 2009, Baltimore County exercised the first of the two three-year extensions for the period from September 15, 2009 through September 14, 2012. BCDC pays us a base monthly fee, which may be adjusted for changes in inmate population levels. Under the agreement, we are subject to mandatory staffing requirements. The agreement also contains provisions that allow the BCDC to assess penalties if certain staffing criteria are not maintained and certain liquidated damages in the event certain performance standards are not met. We also provide, at our own expense, a performance bond for 100% of the annual amount of the awarded contract, as well as a payment bond for approximately 25% of the annual amount of the awarded contract. BCDC may terminate the agreement upon ninety days written notice without cause and may immediately terminate the agreement for a material breach of the agreement subject to certain cure provisions.

Pima County Detention Center Contract.  We entered into a Correctional Health Services Agreement with Pima County, Arizona on August 7, 2008, to provide medical services to the inmates at the Pima County Adult Detention Center (“PCDC”) for an initial term of twenty-three months retroactive to August 1, 2008.  On November 17, 2009, the Pima County Board of Supervisors approved extension of the agreement for an additional twenty-four months through June 30, 2012.  Under the terms of the contract, we provide an inmate medical services platform that includes: staffing of physicians, mid-level providers, nurses and clerical personnel; as well as dental services, mental and behavioral health screening and management services, and ancillary services, such as laboratory and pharmacy services. In addition, we manage offsite specialist and hospital services. The PCDC pays us a base monthly fee, which may be adjusted for changes in inmate population. Under the agreement, we are subject to mandatory staffing requirements. The agreement also contains provisions that allow the PCDC to assess penalties if certain staffing criteria are not maintained and impose certain liquidated damages in the event certain performance standards are not met. We also provide, at our own expense, a performance bond for $500,000. The contract may be terminated by Pima County at any time and without cause by providing ninety days advance written notice.

Sedgwick County Detention Center Contract.  We entered into a Services Agreement with the Board of County Commissioners of Sedgwick County, Kansas (“Sedgwick County”), on January 31, 2005, for a period of two years. On June 1, 2007, the agreement was amended to extend the basic term through December 31, 2009.  On October 22, 2009, the Sedgwick County Board of Bids and Contracts approved a new contract for five years through December 31, 2014.  Sedgwick County pays us a base monthly fee, which may be adjusted for changes in inmate population levels. Under the agreement, we are subject to mandatory staffing requirements. The agreement also contains a provision that allows Sedgwick County to assess penalties if certain staffing criteria are not maintained. Sedgwick County may terminate the agreement upon thirty days written notice without cause. Either party may immediately terminate the agreement for a material breach of the agreement subject to certain cure provisions.

 
7

 

Employees

As of December 31, 2009, we had approximately 454 full-time and 52 part-time employees, 357 per diem employees, and 59 position contractors. We provide all full-time employees with a comprehensive benefits package including medical insurance, education stipend, dental insurance, 401(k) and paid vacation. We believe that our relations with our employees are good. None of our employees belong to a union.

Executive Officers of the Company

Certain information regarding each of our executive officers is set forth below.

Name
 
Age
 
Position
Richard W. Turner, Ph.D.
 
63
 
Chairman, Chief Executive Officer and Director
( Parent and Operating Subsidiaries )
         
Howard M. Haft, MD
 
60
 
Executive Vice President and Chief Medical Officer
( Parent )
         
Thomas W. Fry
 
65
 
Chief Financial Officer and Secretary
( Parent and Operating Subsidiaries )
 
Richard Turner, Ph.D. - Chairman, Chief Executive Officer and Director of Parent and Operating Subsidiaries

Dr. Turner has been our Chairman, Chief Executive Officer and a Director since May 2008. Prior to May 2008 he served as President and Chief Executive Officer. Prior to consulting for Pace Health Management Systems, Inc., our predecessor in interest, in May 2006, Dr. Turner served as President and Chief Executive Officer of EyeTel Imaging, Inc. from January 2004 to May 2006. Prior to January 2004, Dr. Turner served as President and Chief Executive Officer of BEI Medical Systems Company, Inc. (“BEI Medical”), a company engaged in the development and marketing of a minimally invasive endometrial ablation system. BEI Medical was sold to Boston Scientific Corp. for approximately $95 million in 2002.  Dr. Turner has held executive leadership positions in the medical industry for approximately 25 years, including President and Director of CooperLaserSonics, Inc., President of CooperVision, Inc., President, Chief Executive Officer and Director of Pancretec, Inc. (sold to Abbott Labs, Inc.) and President of Kay Laboratories (sold to Baxter, Inc.). Dr. Turner graduated from Old Dominion University with a Bachelor of Science degree, earned his M.B.A. from Pepperdine University and earned his Ph.D. from Berne University.

Howard Haft, MD - Executive Vice President and Chief Medical Officer of Parent

Dr. Haft, who has served as our Executive Vice President and Chief Medical Officer since January 2007, is a founder of Conmed, Inc. and acted as Director and Chief Medical Officer of Conmed, Inc. from 1984 to January 2007. He also serves as the President of the Maryland Healthcare Associates and Georgetown Affiliate Multispecialty Group Practice. He serves on the Board of Directors of Apollo Medical Corporation that provides practice management services to Maryland Healthcare Associates. He also serves as President of the Maryland Foundation for Quality Healthcare, a not for profit corporation providing healthcare education to the underprivileged of Maryland. Dr. Haft earned his M.D. from Pennsylvania State University, performed his residency in Internal Medicine at Brown University, received a Masters in Medical Management from Tulane University, and is recognized as a Certified Physician Executive by the American College of Physician Executives. He is Board Certified in Internal Medicine and Emergency Medicine.

Thomas W. Fry - Chief Financial Officer and Secretary of Parent and Operating Subsidiaries

Mr. Fry has served as our Chief Financial Officer and Secretary since January 26, 2007.  Prior to joining Pace, our predecessor in interest, Mr. Fry served as Chief Financial Officer of Vasomedical, Inc. from September 2003 to September 2006 and as Vice President, Finance and Administration of BEI Medical from September 1997 until December 2002. From October 1992 until November 1997, Mr. Fry was Vice President, Finance and Administration of BEI Medical’s predecessor company of the same name, which merged into BEI Medical in November 1997. Mr. Fry has held various executive financial positions for approximately 27 years, including Corporate Controller of Disctronics Ltd. from 1989 to 1992, Controller and Chief Financial Officer of Cavitron Inc./CUSA, a medical device, engineering and manufacturing subsidiary of CooperLaserSonics, Inc. and Pfizer Inc., from 1986 to 1989, and Manager of Profit Planning and Manufacturing Controller of Chesebrough-Ponds International, from 1979 to 1986. Prior to that time, Mr. Fry was employed by GTE Corporation in various accounting and financial management positions. Mr. Fry graduated from Southeast Missouri State University with a Bachelor of Science degree, and earned his M.B.A. from Pace University.
 
 
8

 

ITEM 1A.      RISK FACTORS
 
You should consider carefully the following risk factors and other information included or incorporated by reference in this Annual Report on Form 10-K. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we deem to be currently immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.
 
OUR ABILITY TO CONTINUE OR EXPAND OUR BUSINESS AND SECURE NEW CONTRACTS TO PROVIDE HEALTHCARE AND MEDICAL SERVICES TO CORRECTIONAL AND DETENTION FACILITIES DEPENDS ON MANY FACTORS OUTSIDE OUR CONTROL.  Our growth is generally dependent upon our ability to obtain new contracts to provide healthcare and medical services to inmates in county correctional and detention facilities.  This possible growth depends on a number of factors we cannot control, including crime rates and sentencing patterns in various jurisdictions as well as continued privatization by state, county and municipal governmental agencies of healthcare services for correctional facilities, and acceptance of such privatization.  There can be no assurance that this market will continue to grow, or that existing contracts will continue to be made available to the private sector which could cause our revenue to decline and harm our business and operating results.

The demand for our services could be adversely affected by the relaxation of enforcement efforts, leniency in conviction and sentencing practices or through the decriminalization of certain activities currently proscribed by our criminal laws. For instance, any changes with respect to drugs and controlled substances or illegal immigration could affect the number of persons arrested, convicted and sentenced, thereby potentially reducing demand for correctional facilities to house them, and thus, reduce the number of inmates receiving medical services. Legislation has been proposed in numerous jurisdictions that could lower minimum sentences for some non-violent crimes and make more inmates eligible for early release based on good behavior. Also, sentencing alternatives under consideration could put some offenders on probation with electronic monitoring who would otherwise be incarcerated. Similarly, reductions in crime rates could lead to reductions in arrests, convictions and sentences requiring incarceration at correctional facilities.

WE PROVIDE CONTRACTED BUSINESS SERVICES. IN ANY CONTRACT BUSINESS, IT IS POSSIBLE A CONTRACT WILL BE TERMINATED, DEFAULTED UPON OR NOT RENEWED. Our top three medical service contracts with county detention centers generated approximately thirty-eight percent of our total revenues for the year ended December 31, 2009. These same clients generated approximately thirty percent of our gross profit. If a contracted detention facility, particularly one of our primary detention facilities, terminates its contract, which generally may be effective between thirty and ninety days prior to the termination date, our business and financial performance may be seriously harmed.

MOST OF OUR CONTRACTS ARE FOR SHORT-TERMS, ARE GENERALLY TERMINABLE WITHOUT CAUSE, AND THE RENEWAL OR EXTENSION OPTIONS MAY NOT BE EXERCISED BY THE GOVERNMENTAL AGENCY.  Our detention center medical services contracts are typically short-term, ranging from one to three years, with renewal or extension options in favor of the contracting governmental agency. Including extension options, we have several medical service contracts subject to renewal in the next twelve months, which accounted for approximately twelve percent of revenue and seventeen percent of the gross profit, respectively, for the year ended December 31, 2009.  We cannot assure you that these or any other contracts will be renewed or that extension options will be exercised. Additionally, the contracting governmental agency typically may terminate a facility contract without cause by giving us adequate written notice. We customarily incur significant development and start-up costs in establishing our services within the new facilities, and the termination or non-renewal of a contract would require an immediate write-off of any unamortized costs associated with the contract, including unamortized costs for service contracts acquired and goodwill, and could have a material adverse effect upon our financial condition, results of operations and liquidity.

OUR CONTRACTS ARE SUBJECT TO GOVERNMENTAL FUNDING.  Our detention center medical services contracts are subject to either annual or bi-annual governmental appropriations. Failure by a governmental agency to receive such appropriations could result in termination of the contract by such agency or a reduction of the fee payable to us. In addition, even if funds are appropriated, delays in payments may occur which could have a material adverse effect on our financial condition, results of operations and liquidity.

 
9

 

AN INCREASE IN INFLATION COULD ADVERSELY AFFECT OUR OPERATING RESULTS.  Some of our contracts provide for annual increases in the fixed base fee based upon changes in the regional medical care component of the Consumer Price Index. In all other contracts that extend beyond one year, we utilize a projection of the future inflation rate of our cost of services when bidding and negotiating the fixed fee for future years. If inflation exceeds projected levels, depending on the contract structure, our profitability could be adversely affected.

OUR INABILITY TO OBTAIN REQUIRED PERFORMANCE AND/OR PAYMENT BONDS MAY LIMIT OUR ABILITY TO MAINTAIN EXISTING CONTRACTS AND ACQUIRE ADDITIONAL CONTRACTS.  In order to expand our business and obtain new facilities' contracts, as well as maintain certain existing contracts, we will need to be able to obtain bonds in certain counties for which we provide our services. In order to obtain such bonds, or renew existing bonds, we are required to fulfill certain financial requirements and standards. To the extent we are unable to fulfill the necessary financial requirements and standards, we may not be able to acquire new facilities' contracts and could lose our existing contracts, all of which could negatively impact our business operations and financial condition.

WE ARE UNCERTAIN AS TO OCCUPANCY LEVELS AT CERTAIN FACILITIES WE SERVICE. A small portion of our revenues are generated under detention center medical services contracts that specify an offset for populations under a specified number. Under such a per diem rate structure, a decrease in occupancy levels could cause a decrease in the facilities' needs for medical services, and therefore, could cause a decrease in revenue and profitability, and may have an adverse effect on our overall financial condition, results of operations and liquidity.

DISTURBANCES AT FACILITIES WE SERVICE WOULD IMPACT US NEGATIVELY.  An escape, riot, epidemic, catastrophic or other disturbance that seriously impacts the health of a large number of inmates at one of our facilities could have a material adverse effect on our financial condition, results of operations and liquidity. As a result of a disturbance, inmates may suffer multiple injuries for which the cost of care may have a temporary, but significant effect on profitability. Approximately ninety percent of our healthcare services' revenues for the year ended December 31, 2009 are operated under caps which provide limits on the cost of exposure; however, multiple events with significant costs may exceed budget targets.

The remaining ten percent of our correctional healthcare services' revenues from continuing operations contain no limits on our exposure for treatment costs related to catastrophic illnesses or injuries to inmates. Although we attempt to compensate for the increased financial risk when pricing contracts that do not contain catastrophic limits for facilities that have not had any catastrophic illnesses or injuries to inmates that exceeded its insurance coverage in the past, we cannot assure you that we will not experience a catastrophic illness or injury of a patient that exceeds its coverage in the future. The occurrence of severe individual cases outside of those catastrophic limits could render contracts unprofitable and could have a material adverse effect on our financial condition and results of operations.

WE MAY EXPERIENCE MALPRACTICE LITIGATION AND OTHER LIABILITY SUITS. Our medical services to correctional and detention facilities exposes us to potential third-party claims or litigation by inmates or other persons for adverse outcomes (medical malpractice), as well as suits related to infringement of their 8th and 14th amendment rights (deliberate indifference and civil rights). It is likely that as we grow, we will be exposed to additional healthcare liability issues. We currently maintain medical professional liability insurance to cover potential malpractice losses, in the amounts of $1,000,000 per incident and $5,000,000 in the aggregate, as well as $1,000,000 general liability coverage. Such insurance is expensive, subject to various coverage exclusions and deductibles and may not be obtainable in the future on terms acceptable to us, or at all.  In addition, a successful claim against us in excess of our insurance coverage could materially harm our business.  Failure to obtain sufficient levels of professional liability insurance at a reasonable price or at all, may expose us to significant losses, which could have a material adverse impact on our financial condition, results of operations or cash flows.

WE MAY INCUR SIGNIFICANT START-UP AND OPERATING COSTS ON NEW CONTRACTS BEFORE RECEIVING RELATED REVENUES, WHICH MAY IMPACT OUR CASH FLOWS AND NOT BE RECOUPED. When we are awarded a contract to provide medical services to a facility, we may incur significant start-up and operating expenses, including the cost of purchasing equipment and staffing the facility, before we receive any payments under the contract. These expenditures could result in a significant reduction in our cash reserves and may make it more difficult for us to meet other cash obligations. In addition, a contract may be terminated prior to its scheduled expiration and as a result, we may not recover these expenditures or realize any return on our investment.

 
10

 

WE UTILIZE TPA AND PROVIDER NETWORKS TO OBTAIN OUT-OF-FACILITY CARE IN VARIOUS MARKETS. SHOULD THOSE NETWORKS BECOME INACCESSIBLE, OUR COSTS FOR PROVIDING THOSE SERVICES WOULD RISE APPROXIMATELY FIFTEEN PERCENT. Our current profit margin is, in part, due to our ability to reduce out-of-facility costs that are defined by contracted networks. Our net costs are typically approximately fifteen percent less than the stated charges for these services. It is important to note that healthcare providers for the general public utilize these same programs. It is unlikely the environment will change, causing the return of payments based on healthcare provider's charges without discounts.  If the contracted networks become inaccessible, or discounting slows, it would negatively impact our operating margins and could have a material adverse effect on us.

CHANGES IN STATE AND FEDERAL REGULATIONS COULD RESTRICT OUR ABILITY TO CONDUCT OUR BUSINESS. We are subject to extensive regulation by both the federal government and the states in which we conduct our business. There are numerous healthcare and other laws and regulations that we are required to comply with in the conduct of our business. These laws may be materially changed in the future or new or additional laws or regulations may be adopted with which we will be required to comply. The cost of compliance with current and future applicable laws, rules and regulations may be significant.

These state and federal laws and regulations that affect our business and operations include, but are not necessarily limited to:
 
 
·
healthcare fraud and abuse laws and regulations, which prohibit illegal referral and other payments;
 
 
·
ERISA and related regulations, which regulate many healthcare plans;
 
 
·
pharmacy laws and regulations;
 
 
·
privacy and confidentiality laws and regulations;
 
 
·
civil liberties protection laws and regulations;
 
 
·
state and national correctional healthcare auditing bodies;
 
 
·
various licensure laws, such as nursing and physician licensing bodies;
 
 
·
drug pricing legislation; and
 
 
·
Medicare and Medicaid reimbursement regulations.
 
We believe we are operating our business in substantial compliance with all existing legal requirements material to the operation of our business. There are, however, significant uncertainties regarding the application of many of these legal requirements to our business, and there cannot be any assurance that a regulatory agency charged with enforcement of any of these laws or regulations will not interpret them differently or, if there is an enforcement action, that our interpretation would prevail. In addition, there are numerous proposed healthcare laws and regulations at the federal and state levels, many of which could materially affect our ability to conduct business or adversely affect our results of operations.

WE ARE SUBJECT TO HIPAA, AND OUR FAILURE TO COMPLY COULD ADVERSELY AFFECT OUR BUSINESS. On August 21, 1996, Congress passed HIPAA. This legislation required the Secretary of the Department of Health and Human Services to adopt national standards for electronic health transactions and the data elements used in such transactions. The Secretary has adopted safeguards to ensure the integrity and confidentiality of such health information. Violation of the standards is punishable by fines and, in the case of wrongful disclosure of individually identifiable health information, imprisonment. Failure to comply with HIPAA could have an adverse effect on our business.

OUR BUSINESS PRACTICES MAY BE FOUND TO CONSTITUTE ILLEGAL FEE-SPLITTING OR CORPORATE PRACTICE OF MEDICINE, WHICH MAY LEAD TO PENALTIES AND ADVERSELY AFFECT OUR BUSINESS. Many of the states in which we operate have laws that prohibit unlicensed persons or business entities, including corporations, from employing physicians or laws that prohibit certain direct or indirect payments or fee-splitting arrangements between physicians and unlicensed persons or business entities. Possible sanctions for violations of these restrictions include loss of a physician's license, civil and criminal penalties and rescission of business arrangements that may violate these restrictions. These statutes vary from state to state, are often vague, and seldom have been interpreted by the courts or regulatory agencies. We review, on an ongoing basis, the applicable laws in each state in which we operate and review our arrangements with our healthcare providers to ensure that these arrangements comply with all applicable laws. We have no assurance that governmental officials responsible for enforcing these laws will not assert that we, or transactions in which we are involved, are in violation of such laws, or that such laws ultimately will be interpreted by the courts in a manner consistent with our interpretations.

 
11

 

GOVERNMENT AGENCIES MAY INVESTIGATE AND AUDIT OUR CONTRACTS AND, IF ANY IMPROPRIETIES ARE FOUND, WE MAY BE REQUIRED TO REFUND REVENUES WE HAVE RECEIVED, OR FOREGO ANTICIPATED REVENUES, AND WE MAY BE SUBJECT TO PENALTIES AND SANCTIONS. Certain government agencies have the authority to audit and investigate our contracts. As part of that process, government agencies may review our performance of the contract, our pricing practices, our cost structure and our compliance with applicable laws, regulations and standards. For contracts that actually or effectively provide for reimbursement of expenses, if an agency determines we have improperly allocated costs to a specific contract, we may not be reimbursed for those costs, and we could be required to refund the amount of any such costs that have been reimbursed. If a government audit asserts improper or illegal activities by us, we may be subject to civil and criminal penalties and administrative sanctions, including termination of contracts, forfeitures of profits, suspension of payments, fines and suspension or disqualification from doing business with certain government entities.

THERE ARE LARGE COMPETITORS IN THE HEALTHCARE INDUSTRY THAT COULD CHOOSE TO COMPETE AGAINST US, REDUCING OUR PROFIT MARGINS OR CAUSING US TO LOSE CUSTOMERS. Existing national correctional healthcare contract companies, local and regional contracting companies, hospitals and integrated health systems are our potential competitors. These companies include well-established companies which may have greater financial, marketing and technological resources than we do, such as Prison Health Services, Inc., Correctional Medical Services, Inc. and Wexford Health Sources, Inc. Increased price competition could result in the loss of customers or otherwise reduce our profit margins and have a material adverse effect on us.

THERE ARE BARRIERS TO ENTRY INTO THE CORRECTIONAL HEALTHCARE SERVICES MARKET WHICH COULD BE OVERCOME RESULTING IN GREATER COMPETITION. The barriers to entrance to compete for contracts are typically five years experience providing the same services and demonstrated financial stability. It would be possible for an investor to purchase an existing experienced company, add capital and quickly become competitive on a national scale.

WE ARE DEPENDENT ON GOVERNMENT APPROPRIATIONS. Our cash flow is subject to the receipt of sufficient funding of, and timely payment by, contracting governmental entities. If the appropriate governmental agency does not receive sufficient appropriations to cover its contractual obligations, it may terminate our contract or delay or reduce payment to us. Any delays in payment, or the termination of a contract, could have an adverse effect on our cash flow and financial condition. In addition, as a result of, among other things, recent economic developments, federal, state and local governments have encountered, and may encounter, unusual budgetary constraints. As a result, a number of state and local governments are under pressure to control additional spending or reduce current levels of spending. Accordingly, we may be requested in the future to reduce our existing per diem contract rates or forego prospective increases to those rates. In addition, it may become more difficult to renew our existing contracts on favorable terms or otherwise.

OUR INABILITY TO REACT EFFECTIVELY TO CHANGES IN THE HEALTHCARE INDUSTRY COULD ADVERSELY AFFECT OUR OPERATING RESULTS. In recent years, the healthcare industry has undergone significant change driven by various efforts to reduce costs, including potential national healthcare reform, trends toward managed care, cuts in Medicare reimbursements, and horizontal and vertical consolidation within the healthcare industry. Proposed changes to the U.S. healthcare system may increase governmental involvement in healthcare and ancillary health services, and otherwise change the way payers, networks and providers conduct business. Healthcare organizations may react to these proposals and the uncertainty surrounding them by reducing or delaying purchases of cost control mechanisms and related services that we provide. Other legislative or market-driven changes in the healthcare system that we cannot anticipate could also materially adversely affect our business. Our inability to react effectively to these and other changes in the healthcare industry could adversely affect our operating results and business. We cannot predict whether any healthcare reform efforts will be enacted and what effect any such reforms may have on us or our customers.

A PROLONGED ECONOMIC SLOWDOWN OR RECESSION COULD ADVERSELY AFFECT OUR BUSINESS AND OPERATING RESULTS. The current economic slowdown may have a negative effect on our business and financial condition and could also result in inadequate payments under our healthcare services contracts. Unfavorable economic conditions also could increase our funding and working capital costs or limit our access to the capital markets, any of which would adversely affect our business, financial condition, operating results or cash flows.
 
 
12

 

NEGATIVE PUBLICITY ABOUT US OR OUR BUSINESS COULD ADVERSELY AFFECT OUR BUSINESS, RESULTS OF OPERATIONS AND ABILITY TO OBTAIN FUTURE BUSINESS. Negative publicity regarding the provision of correctional healthcare services by for-profit companies could adversely affect our results of operations or business. Privatization of healthcare services for correctional facilities may encounter resistance from groups or constituencies that believe that healthcare services to correctional facilities should only be provided by governmental agencies. Negative publicity regarding the privatization of correctional healthcare services or specific alleged actions or inactions of us or other industry participants may result in increased regulation and legislative review of industry practices that further increase our costs of doing business and adversely affect its results of operations by:
 
 
·
adversely affecting our ability to market our services;
 
 
·
placing pressure on certain of our clients either to force such clients to change the way they do business with us or sever their relationship with us altogether;
 
 
·
increasing the regulatory burdens under which we operate;
 
 
·
increasing our exposure to litigation; or
 
 
·
requiring us to change our services.
 
Moreover, negative publicity relating to us in particular also may adversely affect our ability to renew or maintain existing contracts or to obtain new contracts, which could have a material adverse effect on our business.

THE CONTINUED SERVICES AND LEADERSHIP OF OUR SENIOR MANAGEMENT IS CRITICAL TO OUR ABILITY TO MAINTAIN GROWTH AND ANY LOSS OF KEY PERSONNEL COULD ADVERSELY AFFECT OUR BUSINESS. The future of our business depends, to a significant degree, on the skills and efforts of our senior executives, in particular, Dr. Richard Turner, our Chairman and Chief Executive Officer and Dr. Howard Haft, MD, MMM, CPE, our Executive Vice President and Chief Medical Officer. If we lose the services of any of our senior executives, and especially if any of our executives join a competitor or form a competing company, it could result in a setback to our operating plan and our business and financial performance could be seriously harmed.

We have executed employment agreements with Dr. Haft and Dr. Turner, effective as of the closing of the Acquisition, which include, except for Dr. Turner's employment agreement, noncompetition clauses that expire three years after termination of employment, or during the period that such employee is an owner of any of our issued and outstanding stock.

AS A PUBLIC COMPANY, WE INCUR SUBSTANTIAL ADDITIONAL COSTS AND MAY BE UNABLE TO OPERATE PROFITABLY.  As a publicly-traded company, our business is subject to significant additional costs. These costs include, among other things, additional legal and accounting costs incurred as a result of being a public company plus the additional compliance, reporting, corporate governance and NYSE Amex LLC (the “NYSE Amex”) continued listing requirements and investor relations activities which this entails. Furthermore, the financial, administrative and managerial structures necessary to operate as a public company or the development of such structures require a significant amount of management's time and other resources including financial resources, which may hinder our ability to operate profitably.

OUR REVENUE MARGINS MAY DECREASE DUE TO FIXED REVENUE BASE.  Our existing contracts are primarily structured as fixed fee contracts. The costs of inmate healthcare may fluctuate from what we anticipated due to several variables, including increases in inmate population and increased inmate illness. Such additional costs may not be easily passed through under those contracts containing a fixed fee structure, and therefore, we may not always have sufficient revenue to cover such increased costs. As a result, our revenue margins may fall. If our revenue margins decrease more than one or two percentage points, our ability to perform under our contracts may be limited, which could negatively impact our business operations and financial performance.

WE MAY BE UNSUCCESSFUL IN THE HIRING AND RETENTION OF SKILLED PERSONNEL. The future growth of our business depends on successful hiring and retention of skilled personnel, and we may be unable to hire and retain the skilled personnel we need to succeed. Qualified personnel are in great demand throughout the healthcare industry, thus it is difficult to predict the availability of qualified personnel or the compensation levels required to hire and retain them. We face stiff competition for staffing, which may increase our labor costs and reduce profitability. We compete with other healthcare and service providers in recruiting qualified management and staff personnel for the day-to-day operations of our business, including nurses and other healthcare professionals. In some markets, the scarcity of nurses and other medical support personnel has become a significant operating issue to healthcare businesses. This scarcity may require us to enhance wages and benefits to recruit and retain qualified nurses and other healthcare professionals. Because a significant percentage of our existing contracts are structured as fixed fee contracts, we have a limited ability to pass along increased labor costs to existing customers. The failure to attract and retain sufficient skilled personnel at economically reasonable compensation levels may limit our ability to perform under our contracts, which could lead to the loss of existing contracts or our ability to gain new contracts, and may impair our ability to operate and expand our business, as well as harm our financial performance.

 
13

 

WE MAY EXPERIENCE UNBUDGETED INCREASES IN COSTS RELATED TO THE PROVISION OF HEALTHCARE. Currently, we predict the costs of healthcare based on prior experience and projected increases. The projections for future increases are based on historical trends and expected increases related to the development of new healthcare initiatives, treatments and disease states. For example, recent increases in the use of high cost psychiatric medications have triggered increases in the projected costs of those medications in the bid process. However, mid-cycle increases, such as those associated with the need to use a more expensive antibiotic for a drug resistant infection, or the development of a standard treatment for Hepatitis C, for example, would produce significant cost overruns in pharmacy budgeted expenses.

WE ARE SUBJECT TO NECESSARY INSURANCE COSTS. Workers' compensation, employee health, and medical professional and general liability insurance represent significant costs to us. Because we significantly self-insure for workers' compensation, employee health, medical professional and general liability risks, our insurance expense is dependent on claims experience, our ability to control our claims experience, and in the case of workers' compensation and employee health, rising healthcare costs in general. Further, additional terrorist attacks, such as those on September 11, 2001, and concerns over corporate governance and corporate accounting scandals, could make it more difficult and costly to obtain liability and other types of insurance. Unanticipated additional insurance costs could adversely impact our results of operations and cash flows, and the failure to obtain or maintain any necessary insurance coverage could have a material adverse effect on us.

WE FACE RISKS ASSOCIATED WITH ACQUISITIONS. We intend to grow through internal expansion and through selective acquisitions. We cannot assure you that we will be able to identify, acquire or profitably manage acquired operations or that operations acquired will be profitable or achieve levels of profitability that justify the related investment. We may not realize the anticipated benefits of these acquisitions, or may not realize them in the timeframe expected.  Acquisitions involve a number of special risks, including possible adverse short-term effects on our operating results, diversion of management's attention from existing business, dependence on retaining, hiring and training key personnel, risks associated with unanticipated problems or legal liabilities, and amortization of acquired intangible assets, any of which could have a material adverse effect on our financial condition, results of operations and liquidity.

THE LIABILITY OF OUR OFFICERS AND DIRECTORS IS LIMITED. On March 13, 2007, we reincorporated as a Delaware corporation and we provide our officers and directors indemnification to the fullest extent allowed under the Delaware General Corporation Law (the “DGCL”). We also carry directors and officers liability insurance. As a result of the foregoing, our officers and directors may not be personally liable to us or our stockholders for actions taken or failure to take any action and may otherwise discourage or deter our stockholders from suing our officers or directors even though such actions, if successful, might otherwise benefit us and our stockholders.

WE HAVE LIMITED EXPERIENCE ATTEMPTING TO COMPLY WITH PUBLIC COMPANY OBLIGATIONS, INCLUDING SECTION 404 OF THE SARBANES-OXLEY ACT OF 2002.  As directed by Section 404 of the Sarbanes-Oxley Act of 2002, the SEC has adopted rules requiring public companies to include a report of management on the company's internal controls over financial reporting in their annual reports on Form 10-K. In addition, the registered certified public accounting firm auditing a public company's financial statements must attest to and report on management's assessment of the effectiveness of the company's internal controls over financial reporting. The requirement for a report of management, as currently in effect, was included in our Annual Report on Form 10-K for our fiscal year ended December 31, 2007. The requirement for our auditor to attest on management assessment will apply for the fiscal year ending December 31, 2010. If we are unable to conclude that we have effective internal controls over financial reporting, or if our independent auditors are unable to provide us with an unqualified report as to the effectiveness of our internal controls over financial reporting as required by Section 404 of the Sarbanes-Oxley Act of 2002, investors could lose confidence in the reliability of our financial statements, which could result in a decrease in the value of our securities.

CERTAIN STOCKHOLDERS CAN EXERT CONTROL OVER US AND MAY NOT MAKE DECISIONS THAT FURTHER THE BEST INTERESTS OF ALL STOCKHOLDERS. Our officers, directors and principal stockholders (greater than five percent stockholders) together own a majority of our issued and outstanding common stock. Consequently, these stockholders, if they act individually or together, may exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. In addition, this concentration of ownership may delay or prevent a change of control of us and might affect the market price of our common stock, even when a change of control may be in the best interest of all stockholders. Furthermore, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders, and accordingly, they could cause us to enter into transactions or agreements which we would not otherwise consider.

 
14

 
 
OUR ORGANIZATIONAL DOCUMENTS AND DELAWARE LAW MAKE IT HARDER FOR US TO BE ACQUIRED WITHOUT THE CONSENT AND COOPERATION OF OUR BOARD OF DIRECTORS AND MANAGEMENT. Provisions of our organizational documents and Delaware law may deter or prevent a takeover attempt, including a takeover attempt in which the potential purchaser offers to pay a per share price greater than the current market price of our common stock. Under the terms of our certificate of incorporation, our Board of Directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of such shares. The ability to issue shares of preferred stock could tend to discourage takeover or acquisition proposals not supported by our current Board of Directors. In addition, we are subject to Section 203 of the DGCL, which restricts business combinations with some stockholders once the stockholder acquires fifteen percent or more of our common stock.

TRADING IN OUR COMMON STOCK HAS BEEN LIMITED, SO INVESTORS MAY NOT BE ABLE TO SELL AS MANY OF THEIR SHARES AS THEY WANT AT PREVAILING PRICES. Shares of our common stock are traded on the NYSE Amex market. Approximately 8,649 shares were traded on an average daily trading basis for the year ended December 31, 2009. If limited trading in our common stock continues, it may be difficult for investors once and if the securities are registered, to sell the securities acquired by them. Also, the sale of a large block of our common stock could depress the market price of our common stock to a greater degree than a company that typically has a higher volume of trading of its securities.

THE MARKET PRICE OF OUR COMMON STOCK MAY BE HIGHLY VOLATILE, WHICH MAY LEAD TO LAWSUITS AGAINST US. Our common stock currently trades on the NYSE Amex market under the symbol “CONM”. The trading price of our common stock may be subject to volatility in response to, among other things, quarter-to-quarter variations in our operating results, announcements of new contracts, cancellations of existing contracts or new acquisitions by us or our competitors, changes in financial estimates by securities analysts or other events or factors.  Sales of substantial amounts of our common stock, or the perception that such sales might occur, could also adversely affect prevailing market prices of our common stock.  When the market price of a company's stock drops significantly, stockholders often institute securities class action lawsuits against that company. A lawsuit against us could cause us to incur substantial costs and could divert the time and attention of our management and other resources.

WE MAY NOT BE ABLE TO MEET THE NYSE AMEX’S CONTINUED LISTING STANDARDS AND AS A RESULT, THE NYSE AMEX MAY DELIST OUR SECURITIES FROM QUOTATION ON ITS EXCHANGE, WHICH COULD LIMIT INVESTORS’ ABILITY TO MAKE TRANSACTIONS IN OUR SECURITIES AND SUBJECT US TO ADDITIONAL TRADING RESTRICTIONS. Our securities are currently listed on the NYSE Amex, however we cannot assure you that our securities will continue to be listed on the NYSE Amex if we are unable to meet certain of the continued listing standards.  If the NYSE Amex delists our securities from trading on its exchange, we could face significant material adverse consequences, including:

 
·
a limited availability of market quotations for our securities;
 
 
·
reduced liquidity with respect to our securities;
 
 
·
a determination that our common stock is a “penny stock” (as defined in Rule 3a51-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which will require brokers trading in our common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;
 
 
·
a limited amount of news and analyst coverage for our company; and
 
 
·
a decreased ability to issue additional securities or obtain additional financing in the future.

 
15

 
 
ITEM 1B.
UNRESOLVED STAFF COMMENTS.
 
Not applicable because the Company is a Smaller Reporting Company.
 
ITEM 2.
PROPERTIES.
 

Hanover, Maryland. In December 2007, we entered into a five year office lease agreement for approximately 6,668 square feet of office space to house our executive and administrative offices at an annual rent of $131,693 beginning February 2008  and subject to incremental annual increases up to $148,222 in the final year of the lease, which expires on February 28, 2013, subject to a five-year renewal option.

Newberg, Oregon. In November, 2008, we entered into a sixteen month office lease agreement for office space at an annual rent of $14,400 per year, subject to a one year renewal option.

We believe all of our facilities are well-maintained and in good operating condition and have adequate capacity to meet our current business needs.
 
ITEM 3.
LEGAL PROCEEDINGS.
 
Although we are a party to various claims and legal actions arising in the ordinary course of business, we believe, on the basis of information presently available to us, that the ultimate disposition of these matters will be resolved within our insurance limits and will not likely have a material adverse effect on our consolidated financial position or results of operations.
 
RESERVED.

 
16

 

PART II.
 
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
 
Our common stock has been quoted on the NYSE Amex market under the symbol “CONM” since July 15, 2009.  From March 15, 2007 through July 14, 2009, our common stock was quoted on the OTC Bulletin Board under the symbol “CMHM.OB”.  From May 19, 1998 until March 14, 2007, our common stock was quoted on the OTC Bulletin Board under the symbol “PCES.OB”.  From our initial public offering on April 27, 1995 through May 18, 1998, our common stock was traded on The NASDAQ Small Cap Market.

The following table sets forth the range of high and low sales prices of our common stock by quarter over the last two years. These quotations reflect inter-dealer prices, without retail markup, markdown, or commission and may not reflect actual transactions.

Quarter ended
 
High
   
Low
 
 
3/31/08
    2.80       1.30  
 
6/30/08
    2.40       1.55  
 
9/30/08
    2.75       1.40  
 
12/31/08
    2.80       1.75  
 
3/31/09
    2.50       1.65  
 
6/30/09
    3.90       1.70  
 
9/30/09
    4.40       3.15  
 
12/31/09
    3.45       2.57  

From January 1, 2010 through March 17, 2010, the high and low sales prices of our common stock were $3.60 and $3.00, respectively.

On March 17, 2010, the closing price of our common stock was $3.25.

As of March 17, 2010, there were 66 shareholders of record of our common stock.
 
Dividend Policy

We have declared no cash dividends since inception with respect to our common stock, and have no plans to declare a dividend in the near future.  The payment by us of dividends, if any, in the future, rests within the sole discretion of our Board of Directors.  The payment of dividends will depend upon our earnings, our capital requirements and our financial condition, as well as other relevant factors.
 
SELECTED FINANCIAL DATA.
 
Not applicable because the Company is a Smaller Reporting Company.
 
ITEM 7.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
 
The statements set forth in this Annual Report on Form 10-K, including under the headings “Business”, “Risk Factors”, “Legal Proceedings” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and those incorporated by reference herein which are not historical constitute “Forward Looking Statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Exchange Act, including statements regarding the expectations, beliefs, intentions or strategies for the future of both the Company and its subsidiaries. Such statements may involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from our future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company's future plans, strategies and expectations, are generally identifiable by use of words such as “may,”, “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “plan,” “potential” or “project” or the negative of these words or other variations on these words or comparable terminology. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Forward-looking statements are subject to many risks and uncertainties which could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.  It is possible that the assumptions made by us for purposes of such forward-looking statements may not be valid and that the results may not materialize.  We caution you not to place undue reliance on these forward-looking statements. Such forward-looking statements relate only to events as of the date on which the statements are made. Except to the extent required by applicable laws or rules, we do not undertake any obligation or duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make in future public statements and press releases.

 
17

 

General
 
Prior to January 26, 2007, the Company, formerly known as Pace, was classified as a shell company, had no ongoing operations, minimal operating expenses and no employees.

On January 26, 2007, we acquired Conmed, Inc., a privately-owned provider of correctional healthcare services. Conmed, Inc. was formed as a corporation on June 10, 1987 in the State of Maryland for the purpose of providing healthcare services exclusively to county detention centers located in Maryland. As Conmed, Inc. developed, it accepted more contracts for additional services including mental health, pharmacy and out-of-facility healthcare. In 2000, Conmed, Inc. served more than 50% of the county detention healthcare services market in Maryland. In 2003, Conmed, Inc. elected to seek contracts outside of Maryland and at the time of the Acquisition operated in four states: Kansas, Maryland, Virginia and Washington.  For the fiscal year ended December 31, 2007, Conmed, Inc. had net revenues primarily from medical services provided to correctional institutions of $26,073,040.

As a result of the Acquisition, Conmed, Inc. is a wholly-owned subsidiary of the Company and the business of Conmed, Inc. is now our primary business. On March 13, 2007, the Company changed its name to Conmed Healthcare Management, Inc. In 2008, we  purchased all of the assets of EMDC, a provider of medical services in northwest Oregon and we purchased all of the stock of CMHS, a provider of mental health services in Maryland.  As of December 31, 2009, we were in contract with, and providing medical services in thirty-six counties in seven states including: Arizona, Kansas, Maryland, Oklahoma, Oregon, Virginia and Washington and had net revenues primarily from medical services provided to correctional institutions of $52,784,559.
 
Critical Accounting Policies

Our discussion and analysis of our financial position and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported revenues and expenses during the period.  Actual results could differ from those estimates.

A summary of our critical accounting policies is as follows:

Acquisition
Acquisitions are recorded as required by business combination accounting standards using the purchase method. Under purchase accounting, assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree should be stated on the financial statements at “fair value” (see definition in Fair Value of Financial Instruments section below), with limited exceptions, as of the acquisition date.  This standard requires that intangible assets be recognized as assets apart from goodwill if they meet one of two criteria, (1) the contractual-legal criterion, or (2) the separability criterion.  This standard also requires disclosure of the primary reasons for business combination and the allocation of the purchase price paid to the assets acquired and the liabilities assumed by major balance sheet caption. Goodwill is to be recognized as a residual. If the acquisition-date fair value exceeds the consideration transferred, a gain is to be recognized. The statement generally requires that acquisition costs be expensed as incurred. This standard is effective for business combinations for which the acquisition date is on or after January 1, 2009.

Fair Value of Financial Instruments
Financial instruments include cash, receivables, accounts payable, accrued expenses, deferred revenue and long-term debt. We believe the fair value of each of these instruments approximates their carrying value in the balance sheet as of the balance sheet date. The fair value of current assets and current liabilities is estimated to approximate carrying value due to the short-term nature of these instruments. The fair value of the long-term debt is estimated based on anticipated interest rates which we believe would currently be available to us for similar issues of debt, taking into account our current credit risk and other market factors.  The same assumptions are used to record financial instruments acquired through acquisition at fair value.

 
18

 

Effective January 1, 2008, we adopted the new accounting guidance on fair value measurements. The fair value measurement guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under the fair value measurement guidance as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under the fair value measurement guidance must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:
 
 
·
Level 1 – Quoted prices in active markets for identical assets or liabilities.
 
 
·
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
 
·
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The adoption of the fair value measurement guidance did not have a material impact on our financial statements.  Details related to our adoption of this standard are discussed in Note 6, “Fair Value Measurements”.

Service Contracts Acquired
There are material costs in obtaining a customer list, especially customers with recurring revenue streams. The value of service contracts acquired is represented by the future revenue streams, therefore, the income approach is the most applicable fair value measurement approach to value these assets. The operating income streams of service contracts acquired are calculated based on the net present value of estimated earnings. Operating income streams are estimated on a contract by contract basis and an overall cost factor is used to estimate management expenses.  Service contracts acquired are amortized over the life of each individual contract.

Non-Compete Agreements
Non-compete agreements are generally acquired as part of our acquisition agreements.  Key considerations in estimating the value of non-compete agreements include consideration of the potential losses resulting from such competition, the enforceability of the terms of the agreement, and the likelihood of competition in the absence of the agreement. Non-compete agreements are amortized over the lives of the agreements.

Goodwill 
We record as goodwill the excess of purchase price over the fair value of the identifiable net assets acquired.  Annually, as well as when an event triggering impairment may have occurred, the Company is required to perform a two-step impairment test on goodwill. The first step tests for impairment, while the second step, if necessary, measures the impairment. There have been no indicators of impairment for any of the goodwill. We have elected to perform our annual analysis during the fourth quarter of each fiscal year.

Revenue Recognition
Our principal source of revenue is contracts to provide medical assistance to county and municipal correctional facilities. Deferred revenue represents amounts that may be paid in advance of delivery under these contracts.

Most of our contracts call for a fixed monthly fee. In addition, most contracts have incremental charges based on the average daily population (“ADP”) of the correctional facility or a contractual fee adjustment based on the ADP. Revenues from contracts are recognized ratably for fixed fees, or monthly for contracts with variable charges based on ADP. We have one contract that partially operates on a cost plus basis. The timing of each payment varies per contract. Credit terms are not more than thirty days from the date of invoice.

Certain contracts provide for monthly fee adjustments to reflect any missed hours of work required under terms of the contract. In addition, we may incur liquidated damages related to specific performance measurements required under the contract that we have failed to meet. Reductions in monthly fees resulting from staffing adjustments and liquidated damages are recorded by us as reductions to revenue.

 
19

 
 
Certain contracts include “stop/loss” limits, which create a ceiling to our financial responsibility for an individual inmate's care or a maximum amount in the aggregate for certain categories of medical expenses, whereby we are protected from catastrophic medical losses. In circumstances where a stop/loss is reached, we are reimbursed for any costs incurred over the predetermined stop/loss amount. Any reimbursement received by us is recorded as revenue.
  
Accrued Medical Claims Liability
Medical expenses include the costs associated with medical services provided by off-site medical providers; pharmacy, laboratory and radiology fees; professional and general liability insurance as well as other generally related medical expenses. The cost of medical services provided, administered or contracted for are recognized in the period in which they are provided based in part on estimates for unbilled medical services rendered through the balance sheet date. The Company estimates an accrual for unbilled medical services using available utilization data including hospitalization, one-day surgeries, physician visits and emergency room and ambulance visits and other related costs, which are estimated. Additionally, Company personnel review certain inpatient hospital stays and other high cost medical procedures and expenses in order to attempt to identify costs in excess of the historical average rates. Once identified, reserves are determined which take into consideration the specific facts available at that time.

Actual payments and future reserve requirements will differ from the Company’s current estimates. The differences could be material if significant adverse fluctuations occur in the healthcare cost structure or the Company’s future claims experience. Changes in estimates of claims resulting from such fluctuations and differences between estimates and actual claims payments are recognized in the period in which the estimates are changed or the payments are made.

Stock Compensation
Compensation expense for stock-based awards is recorded over the vesting period at the fair value of the award at the time of grant. The recording of such compensation began on January 1, 2006 for shares not yet vested as of that date and for all new grants subsequent to that date. The exercise price of options granted under our incentive plans is equal to the fair market value of the underlying stock at the grant date. We assume no projected forfeitures on stock-based compensation, since actual historical forfeiture rates on our stock-based incentive awards have been negligible.

Fair Value of Derivative Financial Instruments
Effective January 1, 2009, we adopted derivative accounting on warrants that are indexed to an entity’s own stock. Details related to our adoption of this standard and its impact on our financial position and results of operations are discussed in Note 5, “Fair Value of Warrants”.

Income Taxes
Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Recently Adopted Accounting Standards

Effective with the quarter ended June 30, 2009, we adopted guidance on interim disclosures about fair value of financial instruments and it did not have a material impact on our financial position or results of operations.  This guidance requires disclosures about fair value of financial instruments in interim and annual financial statements.

Effective with the quarter ended September 30, 2009, we adopted The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles.  The FASB Accounting Standards Codification (the “Codification”) became the source of authoritative U.S. GAAP recognized by the Financial Accounting Standards Board (FASB) to be applied by nongovernmental entities.  Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants.  On the effective date the Codification superseded all then-existing non-SEC accounting and reporting standards.  All other non-grandfathered non-SEC accounting literature not included in the Codification became non-authoritative.  This standard was effective for financial statements issued for interim and annual periods ending after September 15, 2009.  In the FASB’s view, the issuance of the Codification did not change GAAP, except for those nonpublic nongovernmental entities that must now apply the American Institute of Certified Public Accountants Technical Inquiry Service Section 5100, “Revenue Recognition”, paragraphs 38-76.

 
20

 

Results of Operations

Year Ended December 31, 2009 Compared to the Year Ended December 31, 2008
The following discussion of financial results below is derived from audited financial statements for the years ended December 31, 2009 and December 31, 2008.

   
For the Year Ended
December 31, 2009
   
For the Year Ended
December 31, 2008
 
   
Amount
   
% of
Revenue
   
Amount
   
% of
Revenue
 
Service contract revenue
  $ 52,784,559       100.0 %   $ 40,550,414       100.0 %
                                 
HEALTHCARE EXPENSES:
                               
Salaries, wages and employee benefits
    29,871,129       56.6 %     21,412,861       52.8 %
Medical expenses
    10,283,969       19.5 %     10,378,753       25.6 %
Other operating expenses
    1,940,000       3.7 %     1,333,425       3.3 %
Total healthcare expenses
    42,095,098       79.7 %     33,125,039       81.7 %
                                 
Gross profit
    10,689,461       20.3 %     7,425,375       18.3 %
                                 
OPERATING EXPENSES:
                               
Selling, general & administrative expenses
    7,720,525       14.6 %     6,359,694       15.7 %
Depreciation and amortization
    1,971,288       3.7 %     2,132,748       5.3 %
Total operating expenses
    9,691,813       18.4 %     8,492,442       20.9 %
                                 
Operating income (loss)
    997,648       1.9 %     (1,067,067 )     (2.6 )%
                                 
OTHER INCOME (EXPENSE)
                               
Interest income
    80,215       0.2 %     154,949       0.4 %
Interest (expense)
    (8,294 )     0.0 %     (7,149 )     0.0 %
Change in fair value of derivatives
    (1,209,715 )     (2.3 )%           0.0 %
Total other income (expense)
    (1,137,794 )     (2.2 )%     147,800       0.4 %
                                 
Loss before income taxes
    (140,146 )     (0.3 )%     (919,267 )     (2.3 )%
                                 
Income tax (benefit)
    (113,000 )     (0.2 )%           0.0 %
                                 
Net (loss)
  $ (27,146 )     (0.1 )%   $ (919,267 )     (2.3 )%

Revenues
Net revenue from medical services provided primarily to correctional institutions for the years ended December 31, 2009 and 2008, was $52,784,559 and $40,550,414, respectively, which represents an increase of $12,234,145 or 30.2%. Net loss was $27,146 or 0.1% of revenue compared to a net loss of $919,267 or 2.3% of revenue for the years ended December 31, 2009 and 2008, respectively, which represented an improvement of $892,121.

Approximately $10,834,081 or 88.6% of the increase in revenue for the year ended December 31, 2009 compared to the prior year resulted from the addition of the following new medical service contracts since December 31, 2007: Caroline County, MD; Chesapeake City, VA; Coos County, OR; Creek County, OK; Douglas County, OR; Pima County, AZ; Washington County, MD; and Western Virginia Regional Jail, VA.  Revenues also increased as a result of the contracts in Oregon which we acquired when we purchased all of the assets of EMDC in February 2008, plus the revenue generated from the acquisition of CMHS on November 4, 2008. Revenue improvement totaling approximately $777,160, or 6.3% of the increase, resulted primarily from expansion of the services provided under a number of our existing contracts in which we were providing services prior to 2008. Price increases related to existing service requirements totaled approximately $1,726,017 or 14.1% of the revenue increase. Partially offsetting the above were decreases in other volume related activities totaling $1,103,113, or 9.0% of revenue, primarily associated with lower stop/loss reimbursements resulting from reduced out of facility medical expenditures in excess of stop/loss limits that are billed back to counties.

 
21

 

Healthcare Expenses
Salaries and employee benefits
Salaries and employee benefits for healthcare employees were $29,871,129 or 56.6% of revenue for the year ended December 31, 2009, compared to $21,412,861 or 52.8% of revenue for the year ended December 31, 2008. The increase in spending for salaries and employee benefits of $8,458,268 or 39.5% is due primarily to the addition of new healthcare employees resulting from new business. Approximately 65% of the increase related to new healthcare employees required to support the staffing requirements for our new medical service contracts as detailed above and approximately 15% in the increase relates to the salaries and employee benefits for the new mental health employees related to the CMHS acquisition in November 2008.  Additional medical services related to previously existing medical service contracts plus cost-of-living and wage and benefit adjustments for existing employees accounted for the remainder of the increase. The increase in salaries and employee benefits as a percentage of revenue is due to a change in the mix of expense for salaries and benefits. Several of our new medical service contracts plus the mental health contracts related to the CMHS acquisition have a higher proportion of staffing services compared to our previously existing contracts.  As a result, these new contracts increased the mix of salaries and employee benefits as a percentage of total revenue.

Medical expenses
Medical expenses for the years ended December 31, 2009 and 2008 were $10,283,969 or 19.5% of revenue and $10,378,753 or 25.6% of revenue, respectively, which represented a decrease of $94,784 or 0.9%. The decrease in spending for medical expenses in absolute dollars, despite the increase in revenue, reflects decreases for reimbursable expenditures for hospitalization. Additionally, the mental health services provided by CMHS, as a subcontractor, to Conmed prior to the acquisition of CMHS on November 4, 2008 were being recorded as independent contractor medical expenses totaling approximately $885,000.  Following the acquisition, those expenses are primarily recorded as salaries and employee benefits. The reduction in spending as a percentage of revenue results from the favorable mix factor generated from the new staffing services and the CMHS acquisition as detailed above. Finally, the new contracts entered into in 2008 and 2009 have a lower ratio of medical expenses compared to our previously existing contracts, which reduced the mix of medical expenses as a percentage of total revenue.

Other operating expenses
Other operating expenses were $1,940,000, or 3.7% of revenue, for the year ended December 31, 2009, compared to $1,333,425, or 3.3% of revenue, for the year ended December 31, 2008. The increase of $606,575 is directly related to the increase in the number of inmates served as a result of the new service contracts and reflects increased spending for employment advertising and recruiting, professional liability insurance, legal expenses and office supplies partially offset by a reduction in travel expenses.

Operating Expenses
Selling, general and administrative expenses
Selling, general and administrative expenses for the years ended December 31, 2009 and 2008 were $7,720,525 or 14.6% of revenue and $6,359,694 or 15.7% of revenue, respectively. The increased expenditure of $1,360,831 reflects an increased investment in additional management and administrative personnel required to support additional new contracts and services added in 2008 and 2009, as well as to sustain the Company during anticipated future growth as well as increased travel and legal expenses. Stock based compensation for the years ended December 31, 2009 and 2008 was $628,618 and $573,775, respectively.

Depreciation and amortization
Depreciation and amortization primarily reflects the amortization of intangible assets related to the acquisition of Conmed, Inc. in January 2007, the purchase of medical service contracts from EMDC in February 2008 and the acquisition of CMHS in November 2008. Amortization of service contracts acquired was $1,370,000, or 2.6% of revenue, for the year ended December 31, 2009, compared to $1,693,000, or 4.2% of revenue, for the year ended December 31, 2008. The decrease primarily reflects a decrease in amortization expense related to the Conmed, Inc. acquisition and the EMDC asset purchase as certain individual contracts acquired have become fully amortized, which was partially offset by amortization expense for mental health service contracts acquired in the CMHS acquisition in November 2008.  Amortization of non-compete agreements was $385,000, or 0.7% of revenue, for the year ended December 31, 2009, compared to $327,333, or 0.8% of revenue, for the year ended December 31, 2008. The increase primarily reflects an additional non-compete agreement related to the acquisition of CMHS. Depreciation expense increased to $216,288 for the year ended December 31, 2009 compared to $112,415 for the prior year due primarily to capital expenditures associated with vehicle purchases, a new corporate accounting system and computer equipment in our Pima County, AZ facility.

 
22

 

Interest income
Interest income was $80,215 for the year ended December 31, 2009 compared to $154,949 in 2008. Average cash balances in 2009 were higher compared to 2008, however the lower interest income reflects reduced short-term interest rates during the period.

Interest expense
Interest expense for the year ended December 31, 2009 and 2008 was $8,294 and $7,149, respectively.

Change in fair value of derivatives
As a result of adopting derivative accounting for warrants effective January 1, 2009, 1,705,000 of our issued and outstanding common stock purchase warrants previously treated as equity were no longer afforded equity treatment and as a result they are now being recorded as a liability based on fair value estimates.  These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the Black-Scholes option pricing model and all changes in the fair value of these warrants will be recognized currently in earnings until such time as the warrants are exercised, amended or expire.  As such, on January 1, 2009, we recorded a cumulative adjustment to reclassify $2,399,538 from additional paid-in capital and $366,612 from retained earnings and recorded a $2,766,150 long-term warrant liability to recognize the fair value of such warrants on such date.

During the year ended December 31, 2009, warrants to purchase 40,000 shares of common stock were exercised generating $12,000 of net proceeds and warrants to purchase 132,333 shares of common stock were exercised by cashless exercise and as a result, a total of 155,783 shares of common stock were issued.  During the year ended December 31, 2009, warrants to purchase 814,570 shares of common stock were amended to remove the provisions that resulted in liability treatment and are now treated as equity.

The following table summarizes the warrant activity subject to fair value accounting for the year ended December 31, 2009:

   
Pre-
Acquisition
Warrants
   
Investor
Warrants @
$0.30 per
share
   
Investor
Warrants @
$2.50 per
share
   
Total
 
Warrants outstanding subject to fair value accounting as of January 1, 2009
    225,000       980,000       500,000       1,705,000  
Warrants exercised
    (2,000 )     (167,000 )     (3,333 )     (172,333 )
Warrants amended
    (223,000 )     (591,570 )     -       (814,570 )
Warrants outstanding subject to fair value accounting as of December 31, 2009
    -       221,430       496,667       718,097  

   
Pre-
Acquisition
Warrants
   
Investor
Warrants @
$0.30 per
share
   
Investor
Warrants @
$2.50 per
share
   
Total
 
Fair value of warrants outstanding as of January 1, 2009
  $ 428,221     $ 1,882,701     $ 455,228     $ 2,766,150  
Realized loss on warrants
    142,017       638,364       7,473       787,854  
Unrealized loss on warrants
          189,885       231,976       421,861  
Fair value of warrants transferred to equity upon amendment
    (562,653 )     (1,670,824 )     -       (2,233,477 )
Fair value of warrants exercised
    (7,585 )     (424,846 )     (10,507 )     (442,938 )
Fair value of warrants outstanding as of December 31, 2009
  $     $ 615,280     $ 684,170     $ 1,299,450  

Income tax expense
As of December 31, 2009, management has evaluated all available evidence, both negative and positive, and has determined that it is more likely than not that all of the deferred tax asset, excluding net operating loss carryforwards and research and development credit carryforwards, will be realized and the remaining valuation allowance is no longer required based upon the following:
 
 
·
the Company’s history of generating taxable income;
 
 
·
taxable income has been increasing year over year during the Company’s history; and

 
23

 
 
 
·
management projects taxable income continuing to increase and believes that it is more likely than not that the Company can continue to generate taxable income in the foreseeable future.

For the year ended December 31, 2009, we recorded an income tax benefit of $113,000 as the result of reversing the valuation allowance of $709,000 and an increase in net deferred tax assets of $129,000.  Our effective tax rate differs from the expected tax rate primarily due to permanent differences related to stock-based compensation, change in valuation allowance and derivatives related to warrants.

Liquidity and Capital Resources

Financing is generally provided by funds generated from our operating activities. Funds used to acquire the EMDC contracts and CMHS were provided by working capital.

Cash Flow for the year ended December 31, 2009 compared to the year ended December 31, 2008
Cash as of December 31, 2009 and December 31, 2008 was $11,056,143 and $7,472,140, respectively.  We believe that our existing cash balances and anticipated cash flows from future operations will be sufficient to meet our normal operating requirements and liquidity needs for the next twelve months.

Cash Flows from Operating Activities
Cash flow from operating activities for the year ended December 31, 2009 totaled $4,308,372, reflecting a net loss of $27,146 offset by $2,971,621 in adjustments for non-cash expenses such as the change in fair value of derivatives of $1,209,715, amortization of $1,755,000 and stock-based compensation of $628,618 partially offset by deferred income taxes of $838,000.  Changes in working capital components generated an additional $1,363,897, reflective of increases in accounts payable of $409,239, accrued expenses of $852,421, income taxes payable of $117,620 and deferred revenue of $456,911 partially offset by an increase in prepaid expenses of $573,662.  The increase in accounts payable resulted primarily from the timing of vendor payments in relation to year end.  The increase in accrued expenses resulted primarily from the addition of new healthcare employees required to support the increased staffing requirements from our new medical service contracts in addition to the wage accrual covering one additional day as compared to December 31, 2008 and increased accruals associated with legal expenses.  The increase in income taxes payable resulted primarily from our increased taxable income, resulting in taxes payable in excess of scheduled estimated tax payments.  The increase in deferred revenue resulted primarily from an increase in advance customer payments for services to be provided in the future.  The increase in prepaid expenses resulted primarily from the prepayment of our annual professional liability insurance policy in October.

Cash flow from operating activities for the year ended December 31, 2008 totaled $2,810,990, reflecting a net loss of $919,267 offset by $2,153,780 in adjustments for non-cash expenses such as amortization, stock-based compensation and deferred income taxes and $1,576,477 in changes in working capital components because of increases in accrued expenses, accounts payable and deferred revenue partially offset by increases in accounts receivable and prepaid expenses.  The increase in accrued expenses resulted primarily from increases in estimated medical expenses resulting primarily from the increase in medical service contracts and accrued wages resulting primarily from the addition of new healthcare employees required to support the increased staffing requirements from our new medical service contracts in addition to the wage accrual covering two additional days as compared to 2007 as well as the accrued purchase price adjustment related to the CMHS acquisition.  The increase in accounts receivable and accounts payable resulted primarily from the increase in revenues and expenses resulting primarily from the increase in medical service contracts.  The increase in deferred revenue was primarily the result of new medical service contracts with payments in advance.  The increase in income taxes payable resulted primarily from the decreased loss which resulted in an increased taxable income.

Cash Flows from Investing Activities
Cash flow from investing activities for the year ended December 31, 2009 used $567,953.  Purchases of property and equipment used $292,562 primarily for purchases of vehicles, computer equipment and medical equipment.  The acquisition of CMHS used $187,891 primarily related to payment of the holdback.  Service contract extension costs used $87,500.

Cash flow from investing activities for the year ended December 31, 2008 used $2,439,869. The acquisition of CMHS and the purchase of EMDC’s contracts used $1,767,855 and $245,853, respectively. Purchases of property and equipment primarily related to the new office facility in Hanover, Maryland used $426,161.

 
24

 

Cash Flows from Financing Activities
Cash flow from financing activities for the year ended December 31, 2009 used $156,416.  Proceeds from the exercise of warrants and stock options of $48,812 were offset by $100,000 used to pay off the line of credit we assumed with the CMHS acquisition and $105,228 used to pay off all other loans.

Cash flow from financing activities for the year ended December 31, 2008 used cash of $35,701. Borrowings on the line of credit of $39,903 were offset by payments on loans payable of $75,604.

Loans
As of December 31, 2009, we had no outstanding loans.

Off Balance Sheet Arrangements
We are required to provide performance and payment guarantee bonds to county governments under certain contracts. As of December 31, 2009, we had three performance bonds totaling $8,042,424 and two payment bonds for $2,855,537, totaling $10,897,961. The surety issuing the bonds has recourse against our assets in the event the surety is required to honor the bonds.

Contractual Obligations
The following table presents our expected cash requirements for contractual obligations outstanding as of December 31, 2009:
 
   
Total
   
Current
   
2 - 3 years
   
4 - 5 years
   
Thereafter
 
Equipment leases
    125,189       53,145       65,474       6,570        
Automobile leases
    39,996       28,388       11,608              
Office space leased
    472,113       168,344       291,417       12,352        
Total
  $ 637,298     $ 249,877     $ 368,499     $ 18,922     $  
 
Effects of Inflation
We do not believe that inflation and changing prices over the past three years have had a significant impact on our revenue or results of operations.

Potential Future Service Contract Revenue
As of December 31, 2009, we have entered into 58 agreements with county and municipal governments to provide medical and healthcare services primarily to county and municipal correctional institutions. Most of these contracts are for multiple years and include option renewal periods which are, in all cases, at the county's or municipality’s option. The original terms of the contracts are from one to nine years. These medical service contracts have potential future service contract revenue of $162 million as of December 31, 2009, with a weighted-average term of 3.8 years, of which approximately $60 million relates to the initial contract period and approximately $102 million relates to the option renewal periods.
 
ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
 
Not applicable because the Company is a Smaller Reporting Company.

 
25

 
 
ITEM 8. 
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
27
   
CONSOLIDATED FINANCIAL STATEMENTS
 
Consolidated Balance Sheets
28
Consolidated Statements of Operations
29
Consolidated Statements of Shareholders' Equity
30
Consolidated Statements of Cash Flows
31
Notes to Consolidated Financial Statements
33

 
26

 
 
 
To the Board of Directors and Shareholders
Conmed Healthcare Management, Inc. and Subsidiaries

We have audited the accompanying consolidated balance sheets of Conmed Healthcare Management, Inc. and subsidiaries as of December 31, 2009 and 2008, and the related consolidated statements of operations, shareholders' equity and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Conmed Healthcare Management, Inc. as of December 31, 2009 and 2008, and the results of their operations and their cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.
 
As described in Note 5 to the consolidated financial statements, effective January 1, 2009, Conmed Healthcare Management, Inc. adopted the provisions of Accounting Standards Codification Topic 815-40 and reclassified certain warrants previously classified as an equity instrument to a liability.
 
We were not engaged to examine management’s assessment of the effectiveness of Conmed Healthcare Management, Inc.’s internal control over financial reporting as of December 31, 2009, included in the accompanying Annual Report on Form 10-K and, accordingly, we do not express an opinion thereon.

/s/ McGladrey & Pullen, LLP
Des Moines, Iowa
March 25, 2010

 
27

 

CONMED HEALTHCARE MANAGEMENT, INC. AND SUBSIDIARIES
 
CONSOLIDATED BALANCE SHEETS

   
December 31, 2009
   
December 31, 2008
 
ASSETS
           
CURRENT ASSETS
           
Cash and cash equivalents
  $ 11,056,143     $ 7,472,140  
Accounts receivable
    2,278,074       2,375,583  
Prepaid expenses
    865,261       291,599  
Deferred taxes
    102,000        
Total current assets
    14,301,478       10,139,322  
PROPERTY AND EQUIPMENT, NET
    605,578       529,304  
DEFERRED TAXES
    1,381,000       645,000  
OTHER ASSETS
               
Service contracts acquired, net
    984,000       2,004,000  
Non-compete agreements, net
    436,667       821,667  
Goodwill
    6,263,705       6,254,544  
Deposits
    11,549       15,408  
Total other assets
    7,695,921       9,095,619  
    $ 23,983,977     $ 20,409,245  
                 
LIABILITIES AND SHAREHOLDERS' EQUITY
               
CURRENT LIABILITIES
               
Accounts payable
  $ 1,489,498     $ 1,080,259  
Accrued expenses
    4,146,940       3,210,749  
Deferred revenue
    1,018,645       561,734  
Notes payable, current portion
          170,228  
Income taxes payable
    550,000       432,380  
Total current liabilities
    7,205,083       5,455,350  
NOTES PAYABLE, LONG-TERM
          35,000  
DERIVATIVE FINANCIAL INSTRUMENTS
    1,299,450        
SHAREHOLDERS' EQUITY
               
Preferred stock no par value; authorized 5,000,000 shares; issued and outstanding zero shares as of December 31, 2009 and December 31, 2008
           
Common stock, $0.0001 par value, authorized 40,000,000 shares; issued and outstanding 12,629,572 and 12,457,539 shares as of December 31, 2009 and 2008, respectively
    1,263       1,246  
Additional paid-in capital
    37,829,900       36,875,610  
Retained (deficit)
    (22,351,719 )     (21,957,961 )
Total shareholders' equity
    15,479,444       14,918,895  
    $ 23,983,977     $ 20,409,245  

See Notes to Consolidated Financial Statements.

 
28

 

 
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2009 AND 2008

   
2009
   
2008
 
             
Service contract revenue
  $ 52,784,559     $ 40,550,414  
                 
HEALTHCARE EXPENSES:
               
Salaries, wages and employee benefits
    29,871,129       21,412,861  
Medical expenses
    10,283,969       10,378,753  
Other operating expenses
    1,940,000       1,333,425  
Total healthcare expenses
    42,095,098       33,125,039  
                 
Gross profit
    10,689,461       7,425,375  
                 
Selling and administrative expenses
    7,720,525       6,359,694  
Depreciation and amortization
    1,971,288       2,132,748  
Total operating expenses
    9,691,813       8,492,442  
                 
Operating income (loss)
    997,648       (1,067,067 )
                 
OTHER INCOME (EXPENSE)
               
Interest income
    80,215       154,949  
Interest (expense)
    (8,294 )     (7,149 )
Change in fair value of derivatives
    (1,209,715 )      
Total other income (expense)
    (1,137,794 )     147,800  
                 
Loss before income taxes
    (140,146 )     (919,267 )
Income tax (benefit)
    (113,000 )      
Net (loss)
  $ (27,146 )   $ (919,267 )
                 
(LOSS) PER COMMON SHARE
               
Basic and diluted
  $ (0.00 )     (0.08 )
                 
WEIGHTED-AVERAGE SHARES OUTSTANDING
               
Basic and diluted
    12,566,382       12,090,399  
 
See Notes to Consolidated Financial Statements.

 
29

 

CONMED HEALTHCARE MANAGEMENT, INC.  AND SUBSIDIARIES
YEARS ENDED DECEMBER 31, 2009 AND 2008

   
Preferred
   
Preferred
   
Common
   
Common
   
Additional
   
Retained
Earnings
       
   
Stock
   
Stock
   
Stock
   
Stock
   
Paid-In
   
(Accumulated
       
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Deficit)
   
Total
 
Balance, December 31, 2007
    -     $ -       11,943,141     $ 1,194     $ 35,901,874     $ (21,038,694 )   $ 14,864,374  
Issuance of shares for asset purchase of EMDC contracts
    -       -       81,081       9       200,004       -       200,013  
Issuance of shares for stock purchase of CMHS
    -       -       81,317       8       199,992       -       200,000  
Exercise of warrants
    -       -       352,000       35       (35 )     -       -  
Stock option expense
    -       -       -       -       573,775       -       573,775  
Net (loss)
    -       -       -       -       -       (919,267 )     (919,267 )
Balance, December 31, 2008
    -     $ -       12,457,539     $ 1,246     $ 36,875,610     $ (21,957,961 )   $ 14,918,895  
Cumulative effect of change in accounting principle
                                                       
January 1, 2009 reclassification of embedded feature of equity-linked financial instrument to derivative liability
    -       -       -       -       (2,399,538 )     (366,612 )     (2,766,150 )
Exercise of warrants and options
    -       -       172,033       17       491,733       -       491,750  
Stock option expense
    -       -       -       -       628,618       -       628,618  
Amended warrants removing embedded feature of equity-linked financial instrument
    -       -       -       -       2,233,477       -       2,233,477  
Net (loss)
    -       -       -       -       -       (27,146 )     (27,146 )
Balance, December 31, 2009
    -     $ -       12,629,572     $ 1,263     $ 37,829,900     $ (22,351,719 )   $ 15,479,444  

See Notes to Consolidated Financial Statements.

 
30

 
CONMED HEALTHCARE MANAGEMENT, INC. AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2009 AND 2008

   
2009
   
2008
 
CASH FLOWS FROM OPERATING ACTIVITIES
           
Net (loss)
  $ (27,146 )   $ (919,267 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities
               
Depreciation
    216,288       112,415  
Amortization
    1,755,000       2,020,333  
Stock-based compensation
    628,618       573,775  
Change in fair value of derivatives
    1,209,715        
Loss on disposal of property
          2,257  
Deferred income taxes
    (838,000 )     (555,000 )
Changes in working capital components
               
Decrease (increase) in accounts receivable
    97,509       (623,459 )
(Increase) in prepaid expenses
    (573,662 )     (75,083 )
Decrease in deposits
    3,859       45,000  
Increase in accounts payable
    409,239       243,115  
Increase in accrued expenses
    852,421       1,350,865  
Increase in income taxes payable
    117,620       427,380  
Increase in deferred revenue
    456,911       208,659  
Net cash provided by operating activities
    4,308,372       2,810,990  
                 
CASH FLOWS FROM INVESTING ACTIVITIES
               
Purchase of property and equipment
    (292,562 )     (426,161 )
Stock purchase of CMHS, LLC
    (187,891 )     (1,767,855 )
Asset Purchase from EMDC, P.C.
          (245,853 )
Service contract extensions
    (87,500 )      
Net cash (used in) investing activities
    (567,953 )     (2,439,869 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Borrowings on line of credit
          39,903  
Payments on line of credit
    (100,000 )      
Payments on loans payable
    (105,228 )     (75,604 )
Proceeds from exercise of warrants and stock options
    48,812        
Net cash (used in) financing activities
    (156,416 )     (35,701 )
                 
Net increase in cash and cash equivalents
    3,584,003       335,420  
                 
CASH AND CASH EQUIVALENTS
               
Beginning
    7,472,140       7,136,720  
Ending
  $ 11,056,143     $ 7,472,140  
 
 
31

 
 
CONMED HEALTHCARE MANAGEMENT, INC.  AND SUBSIDIARIES
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2009 AND 2008

   
2009
   
2008
 
NON-CASH INVESTING AND FINANCING ACTIVITIES WERE AS FOLLOWS:
           
EMDC Asset Purchase, common stock 81,081 shares
          150,000  
EMDC Asset Purchase, promissory note payable
          132,275  
EMDC Asset Purchase, warrants 80,000 shares
          50,013  
CMHS Stock Purchase, common stock 81,317 shares
          200,000  
CMHS Stock Purchase, debt assumed
          58,333  
    $     $ 590,621  
                 
SUPPLEMENTAL DISCLOUSURES OF CASH FLOW INFORMATION
               
Cash payments for interest
  $ 8,294     $ 7,149  
Income taxes paid
  $ 600,140     $ 127,620  
 
See Notes to Consolidated Financial Statements.
 
 
32

 

CONMED HEALTHCARE MANAGEMENT, INC.
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
NOTE 1.
Nature of Business
 
Nature of Business
Prior to January 26, 2007, Conmed Healthcare Management, Inc. (together with its consolidated subsidiaries, “we”, “us”, “our” or the Company, unless otherwise specified or the context otherwise requires) the Company, formerly known as Pace Health Management Systems, Inc. (“Pace”), was classified as a shell company, had no ongoing operations, minimal operating expenses and no employees.

On January 26, 2007, we acquired Conmed, Inc. (“Conmed, Inc.”), a privately-owned provider of correctional healthcare services (the “Acquisition”). Conmed, Inc. was formed as a corporation on June 10, 1987 in the State of Maryland for the purpose of providing healthcare services exclusively to county detention centers located in Maryland. As Conmed, Inc. developed, it accepted more contracts for additional services including mental health, pharmacy and out-of-facility healthcare. In 2000, Conmed, Inc. served more than 50% of the county detention healthcare services market in Maryland. In 2003, Conmed, Inc. elected to seek contracts outside of Maryland and at the time of the Acquisition operated in four states: Kansas, Maryland, Virginia and Washington.

As a result of the Acquisition, Conmed, Inc. is a wholly-owned subsidiary of the Company and the business of Conmed, Inc. is now our primary business. On March 13, 2007, the Company changed its name to Conmed Healthcare Management, Inc. In 2008, we purchased all of the assets of Emergency Medicine Documentation Consultants, P.C. (“EMDC”), a provider of medical services in northwest Oregon, and we purchased all of the stock of Correctional Mental Health Services, LLC (“CMHS”), a provider of mental health services in Maryland.  As of December 31, 2009, we were in contract with, and providing medical services in thirty-six counties in seven states including: Arizona, Kansas, Maryland, Oklahoma, Oregon, Virginia and Washington.
 
NOTE 2.
Significant Accounting Policies
 
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).  The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported revenues and expenses during the period.  Actual results could differ from those estimates.

A summary of our significant accounting policies is as follows:

Accounting Estimates and Assumptions
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our methods of revenue recognition from contracts are based primarily on estimates as are accrued expenses. Actual results could differ from those estimates.

Acquisition
Acquisitions are recorded as required by business combination accounting standards using the purchase method. Under purchase accounting, assets acquired, liabilities assumed, and any noncontrolling interest in the acquiree should be stated on the financial statements at “fair value” (see definition in Fair Value of Financial Instruments section below), with limited exceptions, as of the acquisition date.  This standard requires that intangible assets be recognized as assets apart from goodwill if they meet one of two criteria, (1) the contractual-legal criterion, or (2) the separability criterion.  This standard also requires disclosure of the primary reasons for business combination and the allocation of the purchase price paid to the assets acquired and the liabilities assumed by major balance sheet caption. Goodwill is to be recognized as a residual. If the acquisition-date fair value exceeds the consideration transferred, a gain is to be recognized. The statement generally requires that acquisition costs be expensed as incurred. This standard is effective for business combinations for which the acquisition date is on or after January 1, 2009.

 
33

 

Service Contracts Acquired
There are material costs in obtaining a customer list, especially customers with recurring revenue streams. The value of service contracts acquired is represented by the future revenue streams, therefore, the income approach is the most applicable fair value measurement approach to value these assets. The operating income streams of service contracts acquired are calculated based on the net present value of estimated earnings. Operating income streams are estimated on a contract by contract basis and an overall cost factor is used to estimate management expenses.  Service contracts acquired are amortized over the life of each individual contract.

Non-Compete Agreements
Non-compete agreements are generally acquired as part of our acquisition agreements.  Key considerations in estimating the value of non-compete agreements include consideration of the potential losses resulting from such competition, the enforceability of the terms of the agreement, and the likelihood of competition in the absence of the agreement. Non-compete agreements are amortized over the lives of the agreements.

Goodwill 
We record as goodwill the excess of purchase price over the fair value of the identifiable net assets acquired.  Annually, as well as when an event triggering impairment may have occurred, the Company is required to perform a two-step impairment test on goodwill. The first step tests for impairment, while the second step, if necessary, measures the impairment. There have been no indicators of impairment for any of the goodwill. We have elected to perform our annual analysis during the fourth quarter of each fiscal year.

Cash and Cash Equivalents
We consider all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At December 31, 2009, cash equivalents consisted of interest-bearing money market accounts at a commercial bank.  At December 31, 2008, cash equivalents consisted of interest-bearing money market accounts and certificates of deposit at a commercial bank.

Concentration of Credit Risk
We maintain cash in bank deposit accounts that at times may exceed federally insured limits. We have not experienced any losses in such accounts.

Fair Value of Financial Instruments
Financial instruments include cash, receivables, accounts payable, accrued expenses, deferred revenue and long-term debt. We believe the fair value of each of these instruments approximates their carrying value in the balance sheet as of the balance sheet date. The fair value of current assets and current liabilities is estimated to approximate carrying value due to the short-term nature of these instruments. The fair value of the long-term debt is estimated based on anticipated interest rates which we believe would currently be available to us for similar issues of debt, taking into account our current credit risk and other market factors.  The same assumptions are used to record financial instruments acquired through acquisition at fair value.

Effective January 1, 2008, we adopted the new accounting guidance on fair value measurements. The fair value measurement guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under the fair value measurement guidance as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under the fair value measurement guidance must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, as follows:
 
 
·
Level 1 – Quoted prices in active markets for identical assets or liabilities.
 
 
·
Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
 
·
Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The adoption of the fair value measurement guidance did not have a material impact on our financial statements.  Details related to our adoption of this standard are discussed in Note 6, “Fair Value Measurements”.

 
34

 
 
Principles of Consolidation
The consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries, Conmed, Inc, Conmed Oregon, Inc and Correctional Mental Health Services, LLC (“CMHS”). All significant intercompany balances and transactions have been eliminated in consolidation.

Revenue Recognition
Our principal source of revenue is contracts to provide medical assistance to county and municipal correctional facilities. Deferred revenue represents amounts that may be paid in advance of delivery under these contracts.

Most of our contracts call for a fixed monthly fee. In addition, most contracts have incremental charges based on the average daily population (“ADP”) of the correctional facility or a contractual fee adjustment based on the ADP. Revenues from contracts are recognized ratably for fixed fees, or monthly for contracts with variable charges based on ADP. We have one contract that partially operates on a cost plus basis. The timing of each payment varies per contract. Credit terms are not more than 30 days from the date of invoice.

Certain contracts provide for monthly fee adjustments to reflect any missed hours of work required under terms of the contract. In addition, we may incur liquidated damages related to specific performance measurements required under the contract that we have failed to meet. Reductions in monthly fees resulting from staffing adjustments and liquidated damages are recorded by us as reductions to revenue.

Certain contracts include “stop/loss” limits, which create a ceiling to our financial responsibility for an individual inmate's care or a maximum amount in the aggregate for certain categories of medical expenses, whereby we are protected from catastrophic medical losses. In circumstances where a stop/loss is reached, we are reimbursed for any costs incurred over the predetermined stop/loss amount. Any reimbursement received by us is recorded as revenue.

Accounts Receivables
Receivables are carried at original invoice amount less payment received and an estimate made for doubtful receivables based on a review of all outstanding amounts on a monthly basis. Receivables are generally considered past due 30 days after invoice date. We determine the allowance for doubtful amounts by regularly evaluating individual receivables and considering a creditor's financial condition, credit history and current economic conditions. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received.

Property, Equipment and Software
Property, equipment and software are recorded at cost. Depreciation is provided using the straight-line and accelerated methods of depreciation over the estimated useful lives of three to seven years. It is our policy to capitalize purchases of equipment, fixtures and software that benefit future periods. Repairs and maintenance costs are expensed when incurred.

Accrued Medical Claims Liability
Medical expenses include the costs associated with medical services provided by off-site medical providers; pharmacy, laboratory and radiology fees; professional and general liability insurance as well as other generally related medical expenses. The cost of medical services provided, administered or contracted for are recognized in the period in which they are provided based in part on estimates for unbilled medical services rendered through the balance sheet date. The Company estimates an accrual for unbilled medical services using available utilization data including hospitalization, one-day surgeries, physician visits and emergency room and ambulance visits and other related costs, which are estimated. Additionally, Company personnel review certain inpatient hospital stays and other high cost medical procedures and expenses in order to attempt to identify costs in excess of the historical average rates. Once identified, reserves are determined which take into consideration the specific facts available at that time.

Actual payments and future reserve requirements will differ from the Company’s current estimates. The differences could be material if significant adverse fluctuations occur in the healthcare cost structure or the Company’s future claims experience. Changes in estimates of claims resulting from such fluctuations and differences between estimates and actual claims payments are recognized in the period in which the estimates are changed or the payments are made.

35

 
Stock Compensation
Compensation expense for stock-based awards is recorded over the vesting period at the fair value of the award at the time of grant. The recording of such compensation began on January 1, 2006 for shares not yet vested as of that date and for all new grants subsequent to that date. The exercise price of options granted under our incentive plans is equal to the fair market value of the underlying stock at the grant date. We assume no projected forfeitures on stock-based compensation, since actual historical forfeiture rates on our stock-based incentive awards have been negligible.

Fair Value of Derivative Financial Instruments
Effective January 1, 2009, we adopted derivative accounting on warrants that are indexed to an entity’s own stock. Details related to our adoption of this standard and its impact on our financial position and results of operations are discussed in Note 5, “Fair Value of Warrants”.

Income Taxes
Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Basic and Diluted Earnings (Loss) Per Share
We have adopted guidance on earnings per share which requires us to present basic and diluted income (loss) per share amounts. Basic income (loss) per share is based on the weighted-average number of common shares outstanding during the period. Diluted income (loss) per share is based on the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares consist of stock options and warrants (using the treasury stock method) and convertible preferred stock (using the if-converted method).

New Accounting Pronouncements
Effective with the quarter ended June 30, 2009, we adopted guidance on interim disclosures about fair value of financial instruments and it did not have a material impact on our financial position or results of operations.  This guidance requires disclosures about fair value of financial instruments in interim and annual financial statements.

Effective with the quarter ended September 30, 2009, we adopted The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles.  The FASB Accounting Standards Codification (“Codification”) became the source of authoritative U.S. GAAP recognized by the Financial Accounting Standards Board (“FASB) to be applied by nongovernmental entities.  Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants.  On the effective date the Codification superseded all then-existing non-SEC accounting and reporting standards.  All other non-grandfathered non-SEC accounting literature not included in the Codification became non-authoritative.  This standard was effective for financial statements issued for interim and annual periods ending after September 15, 2009.  In the FASB’s view, the issuance of the Codification will not change GAAP, except for those nonpublic nongovernmental entities that must now apply the American Institute of Certified Public Accountants Technical Inquiry Service Section 5100, “Revenue Recognition”, paragraphs 38-76.
 
NOTE 3.
Business Combination
 
Asset Purchase of EMDC
EMDC owned contracts to provide primarily physician services in six counties in Northwestern Oregon that were serviced by Dr. Robert Tilley. The contracts offered significant growth opportunities since they fit well with the Company’s geographic expansion strategy and overall business model to expand services with existing accounts and leverage the Company’s expertise in providing full on-site staffing, acute care, mental health, pharmacy and management of out-of-facility services.

The purchase of all of the assets of EMDC that occurred on February 29, 2008 (the “Asset Purchase”), was recorded using business combination accounting standards using the purchase method. The allocated cost of the assets acquired was based on their fair value as of that date. The purchase price exceeded the fair value of EMDC’s net assets acquired with the excess amount recorded as goodwill. The results of EMDC’s operations are included in our consolidated financial statements since the date of acquisition.

The purchase price, including related acquisition costs, totaled $555,148.  The purchase price of EMDC was largely determined on the basis of management’s expectations of future earnings and cash flows, resulting in the recognition of goodwill.  Based on management’s estimate, the acquisition of EMDC resulted in $193,148 of goodwill, $242,000 of service contract intangibles having a 1.7 year weighted average amortization period and $120,000 of non-compete agreements having a 2.0 year weighted average amortization period.  This purchase was financed with funds provided by working capital.

 
36

 
 
The following table details the net assets of EMDC acquired:

Service contracts acquired
  $ 242,000  
Non-compete agreements acquired
    120,000  
Goodwill
    193,148  
Total
  $ 555,148  

The following table details the purchase price of EMDC:

EMDC purchase price
     
Cash purchase price
  $ 228,472  
Deal expenses
    17,381  
Net, cash purchase price
    245,853  
Promissory note
    132,275  
Performance adjustment on promissory note
    (22,993 )
Warrants issued
    50,013  
Common stock issued
    150,000  
Total purchase price
  $ 555,148  

Substantially all of the goodwill and intangible assets listed above will be deductible for income tax purposes in future periods.

Acquisition of CMHS
The purchase of all of the stock of CMHS that occurred on November 4, 2008 (the “Stock Purchase”) accelerated the expansion of the Company’s national behavioral healthcare strategy by creating a preeminent behavioral health platform in Maryland. As a result of the Stock Purchase, the Company obtained the needed additional clinical infrastructure required to provide behavioral health services to the Company’s current Maryland contracts at the standard of care the Company’s customers have come to expect.

The Stock Purchase was recorded using business combination accounting standards using the purchase method. The allocated cost of the assets and liabilities was based on their fair value as of that date. The purchase price exceeded the fair value of CMHS's net assets acquired with the excess amount recorded as goodwill. The results of CMHS’s operations are included in our consolidated financial statements since the date of acquisition.

The purchase price, including related acquisition costs, totaled $2,159,223.  The purchase price of CMHS was largely determined on the basis of management’s expectations of future earnings and cash flows, resulting in the recognition of goodwill.  Based on management’s estimate, the acquisition of CMHS resulted in $1,218,219 of goodwill, $756,000 of service contract intangibles having a 2.3 year weighted average amortization period and $280,000 of non-compete agreements having a 5 year weighted average amortization period.  This purchase was financed with funds provided by working capital.  In 2009, we recorded $9,161 in additional acquisition costs and paid $178,730 as a purchase price adjustment.

37

 
The following table details the opening fair value balance sheet for the CMHS acquisition:

CMHS net assets acquired
     
CURRENT ASSETS
     
Cash and cash equivalents
  $ 3,477  
Accounts receivable
    129,700  
Prepaid expenses
    1,682  
Total current assets
    134,859  
PROPERTY AND EQUIPMENT, NET
     5,000  
OTHER ASSETS
        
Service contracts acquired
    756,000  
Non-compete agreements acquired
    280,000  
Goodwill
    1,218,219  
Deposits
    1,710  
Total other assets
    2,255,929  
Total assets
    2,395,788  
CURRENT LIABILITIES ASSUMED
       
Accrued expenses
    118,135  
Notes payable
    118,430  
Total current liabilities
    236,565  
CMHS net assets acquired
    2,159,223  

The following table details the purchase price of CMHS:

CMHS purchase price
     
Cash purchase price
  $ 1,800,000  
Post closing adjustments
    53,320  
Deal expenses
    105,903  
Less: CMHS cash acquired
    (3,477 )
Net, cash purchase price at December 31, 2009
    1,955,746  
Add back: CMHS cash acquired
    3,477  
Common stock issued
    200,000  
Total purchase price
  $ 2,159,223  

The former shareholder of CMHS was required to make an election under Internal Revenue Code (“IRC”) Section 338 (h)(10) to treat the sale as an asset purchase for income tax purposes. This election created additional tax basis in the goodwill and intangible assets.  Substantially all of the goodwill and intangible assets listed above will be deductible for income tax purposes in future periods.

The following selected pro forma information from the statements of operations is prepared assuming we had acquired EMDC and CMHS at the beginning of 2008:

   
2008
 
Revenue
  $ 41,751,667  
Net (loss)
    (851,302 )
Basic and diluted (loss) per share
  $ (0.07 )

The pro forma net loss reflects adjustments made for depreciation and amortization. The pro forma basic and diluted net loss per share have been calculated assuming the common shares issued in connection with the Asset Purchase and Stock Purchase were issued at the beginning of 2008.

38

 
Other Acquisitions Subsequent to December 31, 2009
In January 2010, we purchased all of the assets of a small mobile imaging company to expand the base of services that we provide to our customers, which were previously subcontracted, and we do not expect this acquisition to have a material impact on our financial position or results of operations.
 
NOTE 4.
Common Stock Warrants
 
On January 26, 2007, in a transaction which closed simultaneously with the Acquisition, we completed a private placement (“Private Placement”) of $15,000,000 of units of Series B Convertible Preferred Stock and warrants, of which approximately $8,000,000 of the proceeds of the Private Placement were paid directly to the Conmed, Inc. stockholders as consideration for the sale of Conmed Inc.'s capital stock.   In connection with the Private Placement, we sold to certain “accredited investors” 150 units, each unit consisting of (i) 100 shares of its Series B Convertible Preferred Stock, (ii) a common stock purchase warrant entitling the holder to purchase up to 10,000 shares of its common stock at an exercise price equal to $0.30 per share and (iii) a common stock purchase warrant entitling the holder to purchase up to 3,333 shares of its common stock at an exercise price equal to $2.50 per share (such units, the “Units”). In connection with the sale of the Units, we retained Maxim Group LLC, a NASD member broker-dealer as our exclusive placement agent (the “Placement Agent”). The Placement Agent received a warrant to purchase 5% of the common stock issuable upon conversion of the Units, at an exercise price equal to $2.75 per share of common stock (an aggregate of 300,000 shares).

Pre-Acquisition Warrants @ $0.30 per share
On October 24, 2005, Pace issued 37,500 warrants to purchase common stock, as adjusted for the 1 for 20 reverse stock split. Of these warrants, 30,000 were issued to John Pappajohn, Pace's sole director and acting chairman, and the remaining 7,500 warrants were issued to his designees. The warrants were issued as compensation for past services rendered and all warrants were immediately vested. The warrants had an exercise price of $10.00, which exceeded the market price of Pace's common stock at the time of issuance. The value of the warrants was separately estimated at $0.20 per share or $10,000 based on the Black-Scholes valuation of the call option associated with a five-year warrant. As part of the negotiations for the Private Placement, Mr. Pappajohn relinquished the 30,000 warrants that were issued to him, and the remaining 7,500 warrants issued to his designees were adjusted to 250,000 warrants to purchase common stock exercisable at $0.30 per share, expiring October 23, 2010.

As of January 1, 2009, we had outstanding warrants to purchase an aggregate of 225,000 shares of common stock.  During the year ended December 31, 2009, warrants to purchase 2,000 shares of common stock were exercised by cashless exercise and as a result, a total of 1,854 shares of common stock were issued.  As of December 31, 2009, we had outstanding warrants to purchase an aggregate of 223,000 shares of common stock.  During the year ended December 31, 2008, no warrants were exercised.

Investor Warrants @ $0.30 per share
In connection with the Private Placement, each investor received a warrant to purchase up to a number of shares of common stock equal to 25% of such investor's subscription amount, divided by the conversion price of the Series B Convertible Preferred Stock, with an exercise price equal to $0.30. As a result, we issued to investors warrants to purchase an aggregate of 1,500,000 shares of common stock, exercisable at $0.30 per share, expiring March 13, 2012.

As of January 1, 2009, we had outstanding warrants to purchase an aggregate of 980,000 shares of common stock.  During the year ended December 31, 2009, warrants to purchase 40,000 shares of common stock were exercised for cash and warrants to purchase 127,000 shares of common stock were exercised by cashless exercise and as a result, a total of 153,018 shares of common stock were issued.  As of December 31, 2009, we had outstanding warrants to purchase an aggregate of 813,000 shares of common stock.  During the year ended December 31, 2008, 400,000 warrants were exercised using the cashless exercise function and as a result, 352,000 shares of common stock were issued.

Investor Warrants @ $2.50 per share
In connection with the Private Placement, each investor received a warrant to purchase up to a number of shares of common stock equal to 8.3% of such investor's subscription amount, divided by the conversion price of the Series B Convertible Preferred Stock, with an exercise price equal to $2.50 per share. As a result, we issued to investors warrants to purchase an aggregate of 500,000 shares of common stock, exercisable at $2.50 per share, expiring March 13, 2012.

As of January 1, 2009, we had outstanding warrants to purchase an aggregate of 500,000 shares of common stock.  During the year ended December 31, 2009, warrants to purchase 3,333 shares of common stock were exercised by cashless exercise and as a result, a total of 911 shares of common stock were issued.  As of December 31, 2009, we had outstanding warrants to purchase an aggregate of 496,667 shares of common stock.  During the year ended December 31, 2008, no warrants were exercised.

39

 
Placement Agent Warrants @ $2.75 per share
In connection with the Private Placement, we issued to the Placement Agent, a warrant to purchase 300,000 shares of common stock, or 5% of the common stock issuable upon conversion of the Series B Convertible Preferred Stock, at an exercise price equal to $2.75 per share and expiring January 26, 2012.

As of December 31, 2009 and 2008, no warrants have been exercised and we had outstanding warrants to purchase an aggregate of 300,000 shares of common stock.

Consultant Warrants @ $1.65 per share
In connection with a consulting agreement dated January 28, 2008, we issued to a consultant a warrant to purchase 120,000 shares of common stock at an exercise price of $1.65 per share expiring February 24, 2013. The warrant vests over four (4) years and is contingent upon the continued service to the Company of the warrant holder. One-quarter of the warrant vested on February 24, 2009 and one thirty-sixth of the warrant will vest on the 24th day of each calendar month thereafter for the following 36 months or until such time as the warrant holder is no longer providing service for the Company. The warrant was valued at $66,909 as of the date of grant using the fair value method which will be recorded as stock-based compensation over the vesting period.

As of December 31, 2008, the warrant holder was no longer providing service for the Company and the warrant to purchase 120,000 shares was forfeited. Expense of $14,197 that was recorded in the first and second quarters of 2008 was reversed in the third quarter of 2008.

Consultant Warrants @ $1.85 per share
In connection with the Asset Purchase, we issued warrants to two consultants to purchase an aggregate of 80,000 shares of common stock at an exercise price of $1.85 per share. The warrants vested immediately and expire February 28, 2013. The warrants were valued at $50,013 as of the date of grant using the fair value method. This expense has been included in acquisition costs.

As of December 31, 2009 and 2008, no warrants have been exercised and we had outstanding warrants to purchase an aggregate of 80,000 shares of common stock.

Summary
As of December 31, 2009, we have outstanding warrants to purchase an aggregate of 1,912,667 shares of common stock at an average exercise price of $1.32 and have reserved shares of our common stock for issuance in connection with the potential exercise thereof. During the year ended December 31, 2009, warrants to purchase 40,000 shares of common stock were exercised for cash and warrants to purchase 132,333 shares of common stock were exercised by cashless exercise and as a result, a total of 155,783 shares of common stock were issued.  During the year ended December 31, 2008, warrants to purchase 200,000 shares of our common stock were issued, 400,000 warrants were exercised resulting in the issuance of 352,000 shares of common stock and a warrant to purchase 120,000 shares of our common stock was forfeited.
 
NOTE 5.
Fair Value of Warrants
 
As a result of adopting derivative accounting for warrants, effective January 1, 2009, 1,705,000 of our issued and outstanding common stock purchase warrants previously treated as equity were no longer afforded equity treatment.  As a result, on January 1, 2009, we recorded a cumulative adjustment to reclassify $2,399,538 from additional paid-in capital and $366,612 from retained earnings and recorded a $2,766,150 long-term warrant liability to recognize the fair value of such warrants on such date.  These common stock purchase warrants do not trade in an active securities market, and as such, we estimate the fair value of these warrants using the Black-Scholes option pricing model and the assumptions we use are set forth below.  The risk-free interest rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve and the expected life is based on our estimate of warrant exercises since historical data is not available.  All changes in the fair value of these warrants will be recognized currently in earnings until such time as the warrants are exercised, amended or expire.

Pre-Acquisition Warrants @ $0.30 per share

Black-Scholes assumptions
 
January 1, 2009
 
Expected life (years)
    0.9  
Expected volatility
    82.51 %
Risk-free interest rate
    0.8 %
Expected dividend yield
    0.0 %
 
40

 
As of December 31, 2009, all warrants subject to fair value accounting were exercised or amended to remove the provisions that resulted in liability treatment and all such amended warrants are now treated as equity.  As such, no remaining liability exists for these warrants.

Investor Warrants @ $0.30 per share

Black-Scholes assumptions
 
December 31, 2009
   
January 1, 2009
 
Expected life (years)
    1.5       2.0  
Expected volatility
    79.59 %     82.51 %
Risk-free interest rate
    1.4 %     1.1 %
Expected dividend yield
    0.0 %     0.0 %

Investor Warrants @ $2.50 per share

Black-Scholes assumptions
 
December 31, 2009
   
January 1, 2009
 
Expected life (years)
    1.5       2.0  
Expected volatility
    79.59 %     82.51 %
Risk-free interest rate
    1.4 %     1.1 %
Expected dividend yield
    0.0 %     0.0 %
 
The following table summarizes the warrant activity subject to fair value accounting for the year ended December 31, 2009:

   
Pre-
Acquisition
Warrants
   
Investor
Warrants @
$0.30 per
share
   
Investor
Warrants @
$2.50 per
share
   
Total
 
Warrants outstanding subject to fair value accounting as of January 1, 2009
    225,000       980,000       500,000       1,705,000  
Warrants exercised
    (2,000 )     (167,000 )     (3,333 )     (172,333 )
Warrants amended
    (223,000 )     (591,570 )     -       (814,570 )
Warrants outstanding subject to fair value accounting as of December 31, 2009
    -       221,430       496,667       718,097  

   
Pre-
Acquisition
Warrants
   
Investor
Warrants @
$0.30 per
share
   
Investor
Warrants @
$2.50 per
share
   
Total
 
Fair value of warrants outstanding as of January 1, 2009
  $ 428,221     $ 1,882,701     $ 455,228     $ 2,766,150  
Realized loss on warrants
    142,017       638,364       7,473       787,854  
Unrealized loss on warrants
          189,885       231,976       421,861  
Fair value of warrants transferred to equity upon amendment
    (562,653 )     (1,670,824 )     -       (2,233,477 )
Fair value of warrants exercised
    (7,585 )     (424,846 )     (10,507 )     (442,938 )
Fair value of warrants outstanding as of December 31, 2009
  $     $ 615,280     $ 684,170     $ 1,299,450  

As of December 31, 2009, we had outstanding warrants to purchase an aggregate of 1,912,667 shares of common stock, of which warrants to purchase 718,097 shares of common stock were subject to derivative accounting for warrants, at an average exercise price of $1.82 and have reserved shares of our common stock for issuance in connection with the potential exercise thereof.
 
NOTE 6.
Fair Value Measurements
 
As a result of the adoption of derivative accounting for warrants, the Company is also required to disclose the fair value measurements required by the fair value measurement guidance.  The derivative financial instruments recorded at fair value in the balance sheet as of December 31, 2009 are categorized based upon the level of judgment associated with the inputs used to measure their fair value.

41

 
The following table summarizes the financial liabilities measured at fair value on a recurring basis as of December 31, 2009, segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value:

   
Total
   
Quoted prices in
active markets for
identical assets
(Level 1)
   
Significant other
observable inputs
(Level 2)
   
Significant
unobservable
inputs
(Level 3)
 
Derivative financial instruments
  $ 1,299,450     $     $     $ 1,299,450  

Equity-linked financial instruments consist of stock warrants issued by the Company that contain a strike price adjustment feature.  In accordance with derivative accounting for warrants, we calculated the fair value of warrants using the Black-Scholes option pricing model and the assumptions used are described in Note 5, “Fair Value of Warrants”.  During the year ended December 31, 2009, we recognized a $421,861 unrealized loss and a $787,853 realized loss related to the change in fair value of the financial instruments which is included in Other Income on the Statement of Operations.

The following table reflects the activity for liabilities measured at fair value using Level 3 inputs for the year ended December 31, 2009:

Initial recognition of equity-linked financial instruments as of January 1, 2009
  $ 2,766,150  
Transfers into level 3
     
Transfers out of level 3
    (2,233,477 )
Sales of equity-linked financial instruments
    (442,938 )
Realized loss related to the change in fair value
    787,854  
Unrealized loss related to the change in fair value
    421,861  
Balance as of December 31, 2009
  $ 1,299,450  
 
NOTE 7.
Common Stock Options
 
Common Stock Options
The Board of Directors has adopted, and our stockholders have approved, the 2007 Stock Option Plan (the “2007 Plan”). The 2007 Plan provides for the grant of up to 2,350,000 incentive stock options, nonqualified stock options, restricted stock, stock bonuses and stock appreciation rights. The 2007 Plan is administered by the Board of Directors, which has the authority and discretion to determine: the persons to whom the options will be granted; when the options will be granted; the number of shares subject to each option; the price at which the shares subject to each option may be purchased; and when each option will become exercisable. The options generally vest over three to four years and expire no later than ten years from the date of grant.

The table below reflects option activity for the period indicated:

   
Number of
Shares
   
Weighted-
Average
Exercise Price
per Share
   
Weighted-
Average
Remaining
Contractual
Term 
(Years)
   
Aggregate
Intrinsic 
Value
 
Outstanding, December 31, 2008
    2,013,167     $ 2.20              
Granted
    101,500       3.06                  
Forfeited
    (95,500 )     2.74                  
Cancelled
                           
Exercised
    (16,250 )     2.27                  
Outstanding, December 31, 2009
    2,002,917     $ 2.21       7.46     $ 1,759,198  
                                 
Exercisable at December 31, 2009
    1,305,462     $ 2.17       7.22     $ 1,198,761  
                                 
Remaining shares available for grant
    330,833                          
 
42

 
During the years ended December 31, 2009 and 2008, we recorded stock-based compensation expense net of reversals for forfeited options totaling $628,618 and $573,775, respectively.

As of December 31, 2009, stock-based compensation expense not yet recognized in income totaled $846,895, which is expected to be recognized over a weighted-average remaining period of 1.2 years. The total grant date fair value of stock options vested during the years ended December 31, 2009 and 2008 was $717,659 and $935,836, respectively.

Management intends to issue new shares of common stock upon the exercise of options.

For purposes of estimating the fair value of each option on the date of grant, we utilize the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because our employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in our opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our employee stock options.

The following table presents the weighted-average assumptions, used to estimate the fair values of the stock options granted to employees, using the Black-Scholes option pricing formula: the risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected life is based on our estimate of option exercises since we don’t have historical data.
 
The fair value of our stock-based awards was estimated assuming no expected dividends and the following weighted-average assumptions for the years ended December 31, 2009 and 2008:

   
2009
   
2008
 
Expected life (years)
    6.0       6.0  
Expected volatility
    75.03 %     52.34 %
Risk-free interest rate
    2.3 %     2.9 %
Expected dividend yield
    0.0 %     0.0 %
Weighted-average  fair value of options granted during the period
  $ 2.05     $ 1.19  

The following table summarizes additional information about stock options outstanding and exercisable as of December 31, 2009:

Options Outstanding
   
Options Exercisable
 
Exercise Price
Range
 
Options
Outstanding
   
Weighted-
Average
Remaining
Contractual
Life
   
Weighted-
Average
Exercise
Price
   
 
 
Shares
Exercisable
   
Weighted-
Average
Exercise
Price
 
$1.50 - $1.99
    34,750      
8.15
    $ 1.71       15,928     $ 1.71  
$2.00 - $2.49
    1,691,000      
7.36
    $ 2.07       1,121,435     $ 2.04  
$2.50 - $2.99
    44,500      
7.38
    $ 2.59       38,230     $ 2.57  
$3.00 - $3.49
    232,667      
8.08
    $ 3.23       129,869     $ 3.22  
                                         
      2,002,917      
7.46
    $ 2.21       1,305,462     $ 2.17  
 
43

 
NOTE 8.
Property and Equipment
 
A summary of property and equipment is as follows:

   
December 31,
2009
   
December 31,
 2008
 
Furniture
  $ 245,388     $ 214,299  
Equipment
    147,976       106,078  
Computers
    448,574       342,879  
Vehicles
    200,355       36,087  
Construction in progress
          50,804  
Total
    1,042,293       750,147  
Accumulated depreciation and amortization
    (436,715 )     (220,843 )
Property and equipment, net
  $ 605,578     $ 529,304  
 
NOTE 9.
Accrued Expenses
 
A summary of accrued expenses is as follows:

   
December 31,
2009
   
December 31,
2008
 
Accrued salaries and employee benefits
  $ 2,458,087     $ 2,002,230  
Accrued medical claims liability
    995,624       927,718  
CMHS acquisition holdback liability
          178,730  
Other
    693,229       102,071  
Total accrued expenses
  $ 4,146,940     $ 3,210,749  
 
NOTE 10.
Earnings Per Share
 
The following table sets forth the computation of basic and diluted (loss) per-share for the years ended December 31, 2009 and 2008:

   
2009
   
2008
 
Numerator for basic and diluted earnings per share:
           
Net (loss)
  $ (27,146 )   $ (919,267 )
                 
Denominator:
               
Weighted-average basic shares outstanding
    12,566,382       12,090,399  
                 
(Loss) per common share:
               
Basic and diluted
  $ (0.00 )   $ (0.08 )
 
Common stock warrants and options outstanding totaling 3,915,584 and 4,098,167 shares, respectively, are not included in diluted earnings per common share for the years ended December 31, 2009 and 2008, respectively, as they would have an antidilutive effect upon earnings per common share.
 
NOTE 11.
401(k) Plan
 
We offer a 401(k) plan for the benefit of substantially all of the employees of Conmed, Inc. and Conmed Oregon, Inc. The contributions to the plan include employee voluntary salary reductions, which can be no greater than the maximum deduction allowable for federal income tax reporting purposes. We offer a safe harbor matching contribution of each participant's contribution up to 4% of eligible compensation. We also can provide a profit sharing contribution at our discretion. Expenses related to this plan totaled $181,592 and $120,552 for the years ended December 31, 2009 and 2008, respectively.

44

 
We offer a Simple IRA plan for the benefit of substantially all of the employees of CMHS.  The contributions to the plan include employee voluntary salary reductions, which can be no greater than the maximum deduction allowable for federal income tax reporting purposes. We offer a safe harbor matching contribution of each participant's contribution up to 3% of eligible compensation.  In lieu of a matching contribution, we can provide a nonelective contribution equal to 2% of calendar year compensation.  Expenses related to this plan totaled approximately $27,412 and $2,932 for the years ended December 31, 2009 and 2008, respectively.
 
NOTE 12.
Operating Leases
 
We lease office space and various equipment under certain noncancelable operating leases, which expire at various dates through 2014.

Future minimum annual lease payments at December 31, 2009 are as follows:

Year ending December 31,:
     
2010
  $ 249,877  
2011
    192,718  
2012
    175,781  
2013
    17,110  
2014
    1,812  
Total
  $ 637,298  

Operating lease expense was $325,207 and $278,187 for the years ended December 31, 2009 and 2008, respectively.
 
NOTE 13.
Major Customers and Commitments
 
During the years ended December 31, 2009 and 2008 we had approximate sales with major customers and related approximate receivables (payables) as follows:

   
For the Year Ended
December 31, 2009
   
For the Year Ended
December 31, 2008
 
   
Revenue
   
Receivable
(Payable)
   
Revenue
   
Receivable
 
Company A
  $ 6,076,000     $ 77,000     $ 6,084,000     $ 15,000  
Company B
    9,651,000       (25,000 )     4,216,000       152,000  
Company C
    4,465,000       367,000       4,085,000       327,000  

In connection with our normal contract activities, we are required to acquire performance and payment bonds for certain service contracts. The surety issuing the bonds has recourse against certain assets in the event the surety is required to honor the bonds. The lengths of our bond contracts vary. Most contracts are one year or less, but periodically contracts are obtained which exceed one year. At December 31, 2009, the Company had $10,897,961 in outstanding bonds.
 
NOTE 14.
Amortization Expense
 
Service Contracts Acquired
Projected amortization of service contracts for the next five years:

Year ending
December 31,:
 
Amortization
 
2010
    521,500  
2011
    334,000  
2012
    117,500  
2013
    11,000  
2014
     
    $ 984,000  
 
 
45

 

 
Accumulated amortization of service contracts as of December 31, 2009 and 2008 was $4,864,000 and $3,494,000, respectively.

Service contract amortization expense recognized was $1,370,000 and $1,693,000 for the years ended December 31, 2009 and 2008, respectively.

Non-Compete Agreements
Projected amortization of non-compete agreements for the next five years:

Year ending 
December 31,:
 
Amortization
 
2010
    266,000  
2011
    68,000  
2012
    56,000  
2013
    46,667  
2014
     
    $ 436,667  

Accumulated amortization of non-compete agreements as of December 31, 2009 and 2008 was $963,333 and $578,333, respectively.

Non-compete amortization expense recognized was $385,000 and $327,333 for the years ended December 31, 2009 and 2008, respectively.
 
NOTE 15.
Revenue Recognition
 
Following is a reconciliation of our service contract revenue to net revenue reflecting adjustments related to minimum staffing requirements and liquidated damages as well as stop/loss reimbursements for the years ended December 31,:

   
2009
   
2008
 
Service contract revenue
  $ 52,152,000     $ 39,963,000  
Staffing adjustments and liquidated damages
    (623,000 )     (473,000 )
Stop/loss reimbursements
    1,256,000       1,060,000  
Net revenue
  $ 52,785,000     $ 40,550,000  
 
NOTE 16.
Income Tax Matters
 
The components of income tax expense for the years ended December 31, 2009 and 2008 from continuing operations are as follows:

   
2009
   
2008
 
Current tax expense
  $ 725,000     $ 555,000  
Deferred tax (benefit)
    (838,000 )     (555,000 )
Income tax (benefit)
  $ (113,000 )      
 
 
46

 

Approximate deferred taxes consist of the following components as of December 31, 2009 and 2008:

   
2009
   
2008
 
Deferred tax asset
           
Intangible assets
  $ 1,805,000       1,300,000  
Other timing differences
    233,000       495,000  
      2,038,000       1,795,000  
Less: valuation allowance
          709,000  
Net deferred tax asset
    2,038,000       1,086,000  
                 
Deferred tax liability
               
Goodwill
    (412,000 )     (322,000 )
Depreciation
    (143,000 )     (119,000 )
                 
Deferred tax asset
  $ 1,483,000       645,000  

The Company’s ability to utilize its net operating loss carryforwards (“NOLs”) and research and development credit carryforwards (“RDCs”) is currently limited due to limitations on change of control under Section 382 (“Section 382”) of the IRC.  As of December 31, 2009, management has decided to write-off, for presentation purposes,  the deferred tax assets related to NOLs and RDCs of $5,253,000 and $391,000, respectively, and their associated valuation allowances of $5,253,000 and $391,000, respectively, as the Company cannot utilize these future benefits under current tax law.  As such, those amounts are not presented in the above table.  Additionally, we have retroactively restated, for this presentation, the approximate deferred taxes as of December 31, 2008 and as such, the above table does not include deferred tax assets related to NOLs and RDCs of $6,057,000 and $391,000, respectively, and their associated valuation allowances of $6,057,000 and $391,000, respectively.

As of December 31, 2009, management has evaluated all available evidence, both negative and positive, and has determined that it is more likely than not that all of the deferred tax asset, excluding NOLs and RDCs, will be realized and the remaining valuation allowance is no longer required based upon the following:
 
 
·
the Company’s history of generating taxable income;
 
 
·
taxable income has been increasing year over year during the Company’s history; and
 
 
·
management projects taxable income continuing to increase and believes that it is more likely than not that the Company can continue to generate taxable income in the foreseeable future.

As of December 31, 2008, we recorded a valuation allowance of $709,000 against deferred tax assets at December 31, 2008 to reduce the total to an amount that management believes will more likely than not be realized.  Management applied a valuation allowance against certain deferred tax assets because of a limited history of taxable income and the long-term nature of the deferred tax asset. We recognized $645,000 of deferred tax assets in 2008 for the amount we estimate will be realized in the short term.

The Stock Purchase in November 2008 is being treated as an asset acquisition for federal income tax purposes under IRC Section 338(h)(10), which allows the Company to capitalize and amortize intangible assets for federal income tax purposes over a 15-year period.

 
47

 

The provision for income taxes for the years ended December 31, 2009 and 2008 differs from the approximate amount of income tax benefit determined by applying the U.S. Federal income tax rate to pre-tax loss, due to the following:

   
2009
   
2008
 
Computed federal income tax benefit
  $ (48,000 )   $ (313,000 )
State income taxes
    102,000       45,000  
Other, including permanent differences
    (42,000 )     (6,000 )
Permanent difference related to stock options
    173,000       142,000  
Permanent difference related to derivative financial instruments
    411,000        
Change in valuation allowance
    (709,000 )     132,000  
Total tax (benefit) shown in financial statements
  $ (113,000 )   $  

The Company adopted guidance on accounting for uncertainty in income taxes effective January 1, 2007.  Our Federal, Arizona, Iowa, Kansas, Maryland, Oregon and Virginia tax returns remain open for examination for years subsequent to 2005.  The Company currently has not recorded a liability for uncertain tax positions.
 
NOTE 17.
Related Party Transactions
 
During the fourth quarter of 2009, we recorded a $29,633 accrued liability to Equity Dynamics, Inc., an entity wholly owned by John Pappajohn, a director of the Company, for acquisition advisory services.

 
48

 
 
ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
 
None.
 
ITEM 9A(T).
CONTROLS AND PROCEDURES.
 
Evaluation of Disclosure Controls and Procedures. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding disclosure.

Management's Report on Internal Control over Financial Reporting.  Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) and 15(d)-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes of accounting principles generally accepted in the United States.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company's internal control over financial reporting as of December 31, 2009. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework. Based on this evaluation, our management, with the participation of the Chief Executive Officer and Chief Financial Officer, concluded that, as of December 31, 2009, our internal control over financial reporting was effective.

This Annual Report on Form 10-K does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management's report in this Annual Report.

Changes in Internal Control Over Financial Reporting. During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
ITEM 9B.
OTHER INFORMATION.
 
None.

 
49

 

PART III.
 
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
 
We have adopted a Code of Conduct and Ethics (the “Code”) that applies to all of our officers, directors and employees (including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer) and have posted the Code on our website at www.conmedinc.com. In the event that we have any amendments to or waivers from any provision of the Code applicable to our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, we intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K by posting such information on our website.

Information relating to our executive officers is included in Part I of this Annual Report on Form 10-K, as permitted by General Instruction G(3).  The other information required by this item is incorporated by reference to our definitive proxy statement for our 2010 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2009. If such proxy statement is not filed on or before April 30, 2010, the information called for by this item will be filed as part of an amendment to this Annual Report on Form 10-K on or before such date, in accordance with General Instruction G(3).
 
EXECUTIVE COMPENSATION.
 
The information required by this item is incorporated by reference to our definitive proxy statement for our 2010 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2009. If such proxy statement is not filed on or before April 30, 2010, the information called for by this item will be filed as part of an amendment to this Annual Report on Form 10-K on or before such date, in accordance with General Instruction G(3).
 
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
 
Equity Compensation Plan Information
 
The following table provides information about the shares of our common stock that may be issued upon the exercise of stock options, warrants and other stock rights under all of our equity compensation plans as of December 31, 2009.
 
Plan Category
 
Number of securities
to be issued upon
exercise of
outstanding options,
warrants and rights
 
Weighted average
exercise price of
outstanding options,
warrants and rights (3)
 
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))
 
   
(a)
   
(b)
 
(c)
 
Equity compensation plans approved by security holders (1)
 
2,002,917
 
$
2.21
 
330,833
 
Equity compensation plans not approved by security holders (2)
 
603,000
   
1.72
 
 
Total
 
2,605,917
 
$
2.10
 
330,833
 

(1)
The “Equity compensation plans approved by security holders” consist of the 2007 Stock Option Plan.
(2)
The “Equity compensation plans not approved by security holders” consist of consultant warrants issued in 2008 to two employees of Equity Dynamics, Inc. in connection with the Asset Purchase, placement agent warrants issued in 2007 to Maxim Group LLC in connection with the Private Placement and warrants issued in 2005 to certain designees of John Pappajohn.

 
50

 

Consultant Warrants.  On February 29, 2008, in connection with the Asset Purchase, we issued warrants to purchase an aggregate of 80,000 shares of common stock at an exercise price of $1.85 per share to two employees of Equity Dynamics, Inc., an entity wholly owned by John Pappajohn, a director of the Company.  The warrants vested immediately and expire February 28, 2013. As of December 31, 2009, 80,000 warrants remain outstanding.

Placement Agent Warrants.  In connection with the Private Placement, we issued to the Maxim Group LLC, a warrant to purchase 300,000 shares of common stock, or 5% of the common stock issuable upon conversion of the Series B Convertible Preferred Stock, at an exercise price equal to $2.75 per share and expiring January 26, 2012. As of December 31, 2009, 300,000 warrants remain outstanding.

Pre-Acquisition Warrants.  On October 24, 2005, Pace issued 37,500 warrants to purchase common stock, as adjusted for the 1 for 20 reverse stock split. Of these warrants, 30,000 were issued to John Pappajohn, Pace's sole director and acting chairman, and the remaining 7,500 warrants were issued to his designees. The warrants were issued as compensation for past services rendered and all warrants were immediately vested. The warrants had an exercise price of $10.00, which exceeded the market price of Pace's common stock at the time of issuance. The value of the warrants was separately estimated at $0.20 per share or $10,000 based on the Black-Scholes valuation of the call option associated with a five-year warrant. As part of the Private Placement, Mr. Pappajohn relinquished the 30,000 warrants that were issued to him, and the remaining 7,500 warrants issued to his designees were adjusted to 250,000 warrants to purchase common stock exercisable at $0.30 per share, expiring October 23, 2010.  As of December 31, 2009, 223,000 warrants remain outstanding.

The other information required by this item is incorporated by reference to our definitive proxy statement for our 2010 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2009.  If such proxy statement is not filed on or before April 30, 2010, the information called for by this item will be filed as part of an amendment to this Annual Report on Form 10-K on or before such date, in accordance with General Instruction G(3).
 
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE.
 
The information required by this item is incorporated by reference to our definitive proxy statement for our 2010 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2009.  If such proxy statement is not filed on or before April 30, 2010, the information called for by this item will be filed as part of an amendment to this Annual Report on Form 10-K on or before such date, in accordance with General Instruction G(3).
 
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES.
 
The information required by this item is incorporated by reference to our definitive proxy statement for our 2010 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2009.  If such proxy statement is not filed on or before April 30, 2010, the information called for by this item will be filed as part of an amendment to this Annual Report on Form 10-K on or before such date, in accordance with General Instruction G(3).

 
51

 

PART IV.
 
ITEM 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
 
(a)  (1) and (2). Financial Statements and Financial Statements Schedule.
 
See index to Consolidated Financial Statements under Item 8 in Part II hereof where these documents are listed.
 
(a)  (3).  Exhibits.
 
Exhibit
Number
 
Description
2.1
 
Agreement and Plan of Merger dated February 14, 2007 (4)
     
3.1
 
Certificate of Incorporation of Conmed Healthcare Management, Inc. (4)
     
3.1.1
 
Certificate of Merger effective as of March 14, 2007 (5)
     
3.1.2
 
Articles of Merger effective as of March 14, 2007 (5)
     
3.2
 
Amended and Restated Bylaws (15)
     
4.1
 
Amendment to Certificate of Incorporation defining rights of Series B Convertible Preferred Stock (3)
     
4.2
 
Amendment to Certificate of Incorporation defining rights of Series C Preferred Stock (3)
     
4.3
 
Form of Investor Warrant ($.30) (3)
     
4.4
 
Form of Investor Warrant ($2.50) (3)
     
4.5
 
Form of Common Stock Certificate (6)
     
10.1
 
Stock Purchase Agreement by and among Pace, Conmed and the Conmed Stockholders set forth therein, dated August 2, 2006 (1)
     
10.2
 
Side letter by and among Pace, Conmed and the Conmed Stockholders set forth therein, dated as of January 12, 2007 (2)
     
10.3
 
Form of Subscription Agreement dated January 26, 2007, with Registration Rights, by and among Pace and certain investors in the Private Placement (3)
     
10.4
 
Placement Agency Agreement dated January 16, 2007, by and between Pace and Maxim Group LLC (3)
     
10.5
 
Form of Securities Purchase Agreement dated January 26, 2007, by and among Pace and certain investors in the Private Placement (3)
     
10.6
 
Form of Registration Rights Agreement dated January 26, 2007 by and among Pace and certain investors in the Private Placement (3)
     
10.7
 
Employment Agreement dated January 26, 2007, by and between Richard W. Turner and Pace Health Management Systems, Inc. (7) *
     
10.8
 
Employment Agreement dated January 26, 2007 by and between Howard M. Haft and Pace Health Management Systems, Inc.(7) *
     
10.9
 
Employment Letter Agreement dated August 21, 2006, by and between Thomas Fry and Pace Health Management Systems, Inc. (7) *
 
 
52

 

10.10
 
Form of Employment Letter Agreement dated January 24, 2007, by and between Larry Doll and Conmed Healthcare Management, Inc. (7) *
     
10.11
 
2007 Stock Option Plan of Conmed Healthcare Management, Inc.(4) *
     
10.12
 
Amendment No. 1 to the 2007 Stock Option Plan (16) *
     
10.13
 
Consulting Agreement dated January 26, 2007, by and between Yankee Partners LLC and Pace Health Management Systems, Inc. (8)
     
10.14
 
Health Services Agreement, dated March 14, 2002, by and between Sheriff of Harford County and Conmed, Inc., as amended (8)
     
10.15
 
Medical Services Agreement, dated January 1, 2006, by and between the Board of County Commissioners of Frederick County and Conmed, Inc., as amended (8)
     
10.16
 
Agreement dated April 25, 2005, by and between Howard County and Conmed, Inc., as amended (8)
     
10.17
 
Medical Services Agreement, dated July 1, 2004, by and between the Sheriff of Cecil County and ConMed, Inc., as amended (8)
     
10.18
 
Agreement for Service, dated July 1, 2005, by and between the County of Loudoun and Conmed, Inc., as amended (8)
     
10.19
 
Agreement, dated August 12, 2006, by and between the Board of County Commissioners for Yakima County, Washington and Conmed, Inc. (8)
     
10.20
 
Medical Services Agreement, by and among Conmed, Inc. and Baltimore County, Maryland, dated March 26, 2007 (9)
     
10.21
 
Medical Services Agreement, by and among Conmed, Inc. and Henrico County Virginia, dated May 7, 2007 (9)
     
10.22
 
Amendment to Medical Services Agreement, by and among Conmed, Inc. and Yakima County, Washington, dated April 3, 2007 (10)
     
10.23
 
Contract Renewal Agreement, by and among Conmed, Inc. and Yakima County, Washington, dated September 4, 2007 (10)
     
10.24
 
Amendment to Medical Services Agreement, by and among Conmed, Inc. and Yakima County, Washington, dated September 4, 2007 (10)
     
10.25
 
First Amendment to Services Agreement, by and among Conmed, Inc. and Sedgwick County, Kansas, dated June 1, 2007 (10)
     
10.26
 
Medical Services Agreement, by and among Conmed, Inc. and Yakima County, Washington, dated October 2, 2007 (10)
     
10.27
 
Office Lease Agreement by and between Conmed, Inc, and 7250 Limited Partners, LLLP dated December 10, 2007 (11)
     
10.28
 
Inmate Healthcare Services Agreement, dated March 19, 2008, by and between Conmed, Inc. and the City of Chesapeake, Virginia Sheriff’s Department (12)
 
 
53

 

10.29
 
Medical Service Agreement with Charles County, Maryland dated July 2, 2008 (13)
     
10.30
 
Professional Services Contract with Pima County, Arizona dated August 1, 2008 (13)
     
10.31
 
Inmate Health Services Agreement, effective as of February 1, 2009, by and between Conmed, Inc. and the Western Virginia Regional Jail Authority (14)
     
21
 
Subsidiaries **
     
23.1
 
Consent of McGladrey & Pullen, LLP dated March 25, 2010 **
     
31.1
 
Certification of Registrant’s Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934. **
     
31.2 
 
Certification of Registrant’s Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934. **
     
32.1
 
Certification of Registrant’s Chief Executive Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350. **
     
32.2
 
Certification of Registrant’s Chief Financial Officer pursuant to Rule 13a-14(b)/15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350. **

*
Management contract or compensatory plan or arrangement.
**
Filed herewith
(1)
Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 8, 2006
(2)
Incorporated by reference to the Company’s Current Report on Form 8-K filed on January 17, 2007
(3)
Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 1, 2007
(4)
Incorporated by reference to the Company’s Definitive Proxy Statement on Schedule 14A filed on February 27, 2007
(5)
Incorporated by reference to the Company’s Current Report on Form 8-K filed on March 19, 2007
(6)
Incorporated by reference to the Company’s Annual Report on Form 10-KSB filed on March 29, 2007
(7)
Incorporated by reference to the Company’s Registration Statement on Form SB-2 filed on April 3, 2007
(8)
Incorporated by reference to the Company’s Registration Statement on Form SB-2/A filed on May 10, 2007
(9)
Incorporated by reference to the Company’s Quarterly Report on Form 10-QSB filed August 14, 2007
(10)
Incorporated by reference to the Company’s Quarterly Report on Form 10-QSB filed November 14, 2007
(11)
Incorporated by reference to the Company’s Annual Report on Form 10-KSB filed on March 31, 2008
(12)
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed on May 14, 2008
(13)
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed on November 13, 2008
(14)
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed on May 15, 2009
(15)
Incorporated by reference to the Company’s Current Report on Form 8-K filed on June 3, 2009
(16)
Incorporated by reference to the Company’s Current Report on Form 8-K filed on July 17, 2009
 
 
54

 
 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
Conmed Healthcare Management, Inc.
   
March 25, 2010
 
 
By: 
/s/ Richard W. Turner
 
Richard W. Turner, Chairman and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacity and on the dates indicated.

March 25, 2010
By 
/s/ Richard W. Turner
Richard W. Turner, Chairman and Chief Executive Officer
and Director (Principal Executive Officer)
   
By
/s/ Thomas W. Fry
Thomas W. Fry, Chief Financial Officer and Secretary
(Principal Financial Officer and Principal Accounting Officer)
   
By
/s/ John Pappajohn
John Pappajohn, Director
   
By
/s/ Edward B. Berger
Edward B. Berger, Director
   
By
/s/ Terry E. Branstad
Terry E. Branstad, Director
   
By
/s/ John W. Colloton
John W. Colloton, Director

 
55